{"title": "Publikationen", "author": "Universit\u00e4tsklinikum W\u00fcrzburg", "url": "https://www.ukw.de/hautklinik/forschung/publikationen/", "hostname": "ukw.de", "description": null, "sitename": "Universit\u00e4tsklinikum W\u00fcrzburg", "date": "2020-03-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Publikationen\nAppenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald R, Schartl M, Goebeler M, Meierjohann S (2019)\nIdentification of patient-specific mutations reveals dual pathway activation in most melanoma patients and activated receptor tyrosine kinases in BRAF/NRAS wildtype melanomas.\nCancer 125, 586-600\nMaurus K, Appenzeller S, Roth S, Kuper J, Rost S, Meierjohann S, Arampatzi P, Goebeler M, Rosenwald A, Geissinger E, Wobser M. Panel (2018)\nSequencing Reveals Recurrent Genetic FAS Alterations In Primary Cutaneous Marginal Zone Lymphoma.\nJ Invest Dermatol 138, 1573-1581\nShukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, Neuberg D, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ (2018)\nCancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.\nCell 173, 624-633.e8\nAdam C, Wohlfarth J, Hau\u00dfmann M, Sennefelder H, Rodin A, Maler M, Martin SF, Goebeler M, Schmidt M (2017)\nAllergy-inducing chromium compounds trigger potent innate immune stimulation via ROS-dependent inflammasome activation.\nJ Invest Dermatol 137, 367-376\nAlrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E (2016)\nNFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.\nNat Commun 7, 11724\nPublikationen 2022\nBlazejak C, Stranzenbach R, Gosman J, Gambichler T, Wehkamp U, Stendel S, Klemke CD, Wobser M, Olk J, Nicolay JP, Weyermann M, Stadler R, Assaf C (2022)\nClinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.\nDermatology.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34474414/)\nBrockow K, Wurpts G, Trautmann A (2022)\nPatients with questionable penicillin (beta-lactam) allergy: Causes and solutions.\nAllergol Select 6:33-41.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/35141465/)\nEsnault C, Schrama D, Houben R, Guy\u00e9tant S, Desgranges A, Martin C, Berthon P, Viaud-Massuard MC, Touz\u00e9 A, Kervarrec T, Samimi M (2022)\nAntibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.\nCancers (Basel). 2022 Feb 2;14(3):778.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/35159045/)\nEsnault C, Leblond V, Martin C, Desgranges A, Baltus CB, Aubrey N, Lakhrif Z, Lajoie L, Lantier L, Cl\u00e9menceau B, Sarma B, Schrama J, Houben R, Schrama D, Hesbacher S, Gouilleux-Gruart V, Feng Y, Dimitrov D, Guy\u00e9tant S, Berthon P, Viaud-Massuard MC, Samimi M, Touz\u00e9 A, Kervarrec T (2022)\nAdcitmer\u00ae, a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.\nBr J Dermatol 186: 295-306.\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20770)\nFriedmann Angeli JP, Xavier da Siva TN, Schilling B (2022)\nCD8+ T cells PUF(A)ing the flames of cancer ferroptotic cell death.\nCancer Cell\n[Zur Publikation](https://www.sciencedirect.com/science/article/abs/pii/S1535610822001180?via%3Dihub)\nFusi L, Paudel R, Meder K, Schlosser A, Schrama D, Goebeler M, Schmidt M (2022)\nInteraction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP Modulates Gene Expression and Apoptosis.\nJ Biol Chem doi: https:// doi.org/10.1016/j.jbc.2022.101714\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/35151693/)\nGoebeler M, Bata-Cs\u00f6rg\u0151 Z, De Simone C, Didona B, Remenyik E, Reznichenko N, Stoevesandt J, Ward ES, Parys W, de Haard H, Dupuy P, Verheesen P, Schmidt E, Joly P and the ARGX-113-1701 Investigator Study Group (2022)\nTreatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial.\nBr J Dermatol 186: 429-439\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34608631/)\nGoldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, K\u00f6lblinger P, Bennannoune N, Cohen JV, K\u00e4hler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM (2022)\nChemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.\nEur J Cancer 162: 22-33.\nHofer V, Maurus K, Houben R, Schrama D, Roth S, Goebeler M, Geissinger E, Rosenwald A, Wobser M (2022)\nTreatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.\nJ Cutan Pathol 49: 314-317\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/10.1111/cup.14178?af=R)\nHouben R, Hesbacher S, Sarma B, Schulte C, Sarosi EM, Popp S, Adam C, Kervarrec T, Schrama D (2022)\nInhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs Merkel cell carcinoma cell growth.\nCancer Lett 524: 259-267\n[Zur Publikation](https://www.sciencegate.app/document/10.1016/j.canlet.2021.10.031)\nKempf W, Petrella T, Willemze R, Jansen P, Berti E, Santucci M, Geissinger E, Cerroni L, Maubac E, Battistella M, Goodlad J, Guenova E, Lappalainen K, Ranki A, Craig P, Calonje E, Martin B, Whittaker S, Oschlies I, Wehkamp U, Nicolay JP, Wobser M, Scarisbruck J, Pimpinelli N, Stadler R, Kerl K, Quaglino P, Lin J, Chen L, Beer M, Emanuel P, Dalle S, Robson A (2022)\nClinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.\nBr J Dermatol doi: 10.1111/bjd.20973.\n[Zur Publikation](https://www.researchgate.net/publication/357626201_Clinical_histopathological_and_prognostic_features_of_primary_cutaneous_acral_CD8_T-cell_lymphoma_and_other_dermal_CD8_cutaneous_lymphoproliferations_-_Results_of_an_EORTC_Cutaneous_Lymphoma_Group_Wor)\nKerstan A, Dieter K, Niebergall-Roth E, Dachtler AK, Kraft K, St\u00fccker M, Daeschlein G, J\u00fcnger M, G\u00f6rge T, Meyer-Pannwitt U, Erfurt-Berge C, von Engelhardt C, Klare A, Pfeiffer C, Esterlechner J, Schr\u00f6der HM, Gasser M, Waaga-Gasser AM, Goebeler M, Ballikaya S, Sadeghi S, Murphy GF, Orgill DP, Frank NY, Ganss C, Scharffetter-Kochanek K, Frank MH, Kluth MA (2022)\nAllogeneic ABCB5+ Mesenchymal Stem Cells for Treatment-Refractory Chronic Venous Ulcers: a Phase I/IIa Clinical Trial.\nJID Innovations Jan;2(1):100067.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34870260/)\nKervarrec T, Pissaloux D, Poilane J, Tirode F, Tallet A, Collin C, Tallegas M, Berthon P, Gaboriaud P, Sohier P, Calonje E, Luzar B, Goto K, Cokelaere K, Lamant L, Balme B, Wild R, Neuville A, Deschamps L, Auberger E, Paumier V, Bonte H, Moulonguet I, Plantier F, Cales V, Pinsolle V, Roblet D, Dupuy F, Dallot A, Seris A, Jouary T, Houben R, Schrama D, Hesbacher S, Macagno N, Battistella M, Cribier B, Vergier B, de la Fouchardi\u00e8re A, Jullie ML (2022)\nRecurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.\nJ Pathol 2022 Jan 20.\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/10.1002/path.5872?af=R)\nKervarrec T, Appenzeller S, Samimi M, Sarma B, Sarosi EM, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Benethon N, Bens G, Nardin C, Aubin F, Dinulescu M, Jullie ML, Pek\u00e1r-Lukacs \u00c1, Calonje E, Thanguturi S, Tallet A, Wobser M, Touz\u00e9 A, Guy\u00e9tant S, Houben R, Schrama D (2022)\nMerkel Cell Polyomavirus\u2012Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation.\nJ Invest Dermatol 142: 516-527\n[Zur Publikation](https://portal.research.lu.se/sv/publications/merkel-cell-polyomavirusnegative-merkel-cell-carcinoma-originatin)\nKervarrec T, Ch\u00e9ret J, Paus R, Houben R, Schrama D (2022)\nTransduction-induced overexpression of Merkel cell T antigens in human hair follicles induces formation of pathological cell clusters with Merkel cell carcinoma-like phenotype.\nExp Dermatol 31: 259-260\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/10.1111/exd.14447)\nLodde GC, Jansen P, M\u00f6ller I, Sucker A, Hassel JC, Forschner A, Eckardt J, Meier F, Reinhardt L, K\u00e4hler KC, Ziemer M, Schlaak M, Rahimi F, Schatton K, Meiss F, Gutzmer R, Pf\u00f6hler C, Terheyden P, Schilling B, Sachse M, Heppt MV, Sindrilaru A, Leiter U, Zaremba A, Thielmann CM, Ugurel S, Zimmer L, Hadaschik E, Bechrakis NE, Schadendorf D, Westekemper H, Livingstone E, Griewank KG; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) (2022)\nGenetic characterization of advanced conjunctival melanoma and response to systemic treatment.\nEur J Cancer 166: 60-72\nZur Publikation\nLoh AYT, \u0160poljar S, Neo GYW, Escande-Beillard N, Leushacke M, Luijten MNH, Venkatesh B, Bonnard C, van Steensel MAM, Hamm H, Carmichael A, Rajan N, Carney TJ, Reversade B (2022)\nHuriez syndrome: Additional pathogenic variants supporting allelism to SMARCAD syndrome.\nAm J Med Genet A\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/35212137/)\nMartin E, Mauer I, Malzahn U, Heuschmann PU, Goebeler M, Benoit S (2022)\nComorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study.\nJ Dtsch Dermatol Ges (in press)\nZur Publikation\nMaurus K, Kosnopfel C, Kneitz H, Appenzeller S, Schrama D, Glutsch V, Roth S, Gerhard-Hartmann E, Rosenfeldt M, M\u00f6hrmann L, Fr\u00f6hlich M, H\u00fcbschmann D, Stenzinger A, Glimm H, Fr\u00f6hling S, Goebeler M, Rosenwald A, Kutzner H, Schilling B (2022)\nCutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway.\nBr J Dermatol 186: 553-563\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/10.1111/bjd.20869)\nStoevesandt J, Keita DU, Goebeler M (2022)\nDisease-related burden and long-term outcome in orofacial granulomatosis: observations from a large single-centre cohort.\nClin Exp Dermatol\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/full/10.1111/ced.15124)\nTawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV ; RELATIVITY-047 Investigators (u.a. A. Gesierich) (2022)\nRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.\nN Engl J Med 386(1):24-34\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34986285/)\nThiem A, Has C, Diem A, Klausegger A, Hamm H, Emmert S (2022)\nWundtherapie mit kaltem Plasma bei Epidermolysis bullosa dystrophica.\nHautarzt (im Druck)\n[Zur Publikation](https://link.springer.com/article/10.1007/s00105-021-04883-5)\nZimmermann S, Aghai F, Schilling B, Kraus S, Grigoleit GU, Kalogirou C, Goebeler ME, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O (2022)\nVolumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.\nJ Pharm Biomed Anal 211:114623.\n[Zur Publikation](https://www.sciencedirect.com/science/article/abs/pii/S0731708522000449)\nPublikationen 2021\nBoas PV, Frings V, Gran F, Lesort C, Machado \u00c1, Arianayagam S (2021)\nWhat's new?\nEur J Dermatol. 2021 Apr 1;31(2)\n[Zur Publikation](https://link.springer.com/article/10.1684/ejd.2021.4028)\nDege T, Wobser M, Goebeler M, Reichel A (2021)\nPressure sensitive livid node on the left knee.\nHautarzt. 2021 May 3.\n[Zur Publikation](https://link.springer.com/article/10.1007/s00105-021-04827-z)\nDomogalla L, Beck A, Schulze-Hagen T, Herr R, Benecke J, Schmieder A (2021)\nImpact of an eHealth Smartphone App on the Mental Health of Patients With Psoriasis: Prospective Randomized Controlled Intervention Study.\nJMIR Mhealth Uhealth 9, e28149\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34431478/)\nFan K, Spassova I, Gravemeyer J, Ritter C, Horny K, Lange A, Gambichler T, \u00d8dum N, Schrama D, Schadendorf D, Ugurel S, Becker JC (2021)\nMerkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53.\nOncogene. 2021 Feb;40(5):980-996.\n[Zur Publikation](https://www.nature.com/articles/s41388-020-01576-6)\nFilipski K, Scherer M, Zeiner KN, Bucher A, Kleemann J, Jurmeister P, Hartung TI, Meissner M, Plate KH, Fenton TR, Walter J, Tierling S, Schilling B, Zeiner PS, Harter PN (2021)\nDNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma.\nJ Immunother Cancer. 2021 Jul;9(7)\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34281986/)\nFrings VG, Bauer B, Schuster R, Goebeler M, Presser D, Kerstan A (2021)\nDifferences in anatomical area-specific wound healing in hidradenitis suppurativa/acne inversa after surgery.\nEur J Dermatol 31: 623-629\n[Zur Publikation](https://link.springer.com/article/10.1684/ejd.2021.4148)\nFrings VG, Goebeler M, Schilling B, Kneitz H (2021)\nAberrant cytoplasmic connexin43 expression as a helpful marker in vascular neoplasms.\nJ Cutan Pathol. 2021 May 21.\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/10.1111/cup.14066)\nFrings VG, Roth S, Rosenwald A, Goebeler M, Geissinger E, Wobser M (2021)\nEBER in situ-hybridization in subcutaneous aluminum granulomas/lymphoid hyperplasia: a diagnostic clue to differentiate injection-associated lymphoid hyperplasia from other forms of pseudolymphomas and cutaneous lymphomas.\nJ Cutan Pathol. 48:625-631\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33496022/)\nFrings VG, Sch\u00f6ffski O, Goebeler M, Presser D (2021)\nEconomic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.\nPLOS One (2021), 16(8)\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34347845/)\nGangaev A, Rozeman EA, Rohaan MW, Isaeva OI, Philips D, Patiwael S, van den Berg JH, Ribas A, Schadendorf D, Schilling B, Schumacher TN, Blank CU, Haanen JBAG, Kvistborg P (2021)\nDifferential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.\nProc Natl Acad Sci USA 118(43):e2102849118\n[Zur Publikation](https://www.researchgate.net/publication/356840051_Differential_effects_of_PD-1_and_CTLA-4_blockade_on_the_melanoma-reactive_CD8_T_cell_response)\nGeier J, Schubert S, Schnuch A, Szliska C, Weisshaar E, Kr\u00e4nke B, Werfel T, Ru\u00ebff F, Schr\u00f6der-Kraft C, Buhl T (2021)\nInformation Network of Departments of Dermatology. A negative breakdown test in a fragrance mix I-positive patient does not rule out contact allergy to its fragrance constituents.\nContact Dermatitis. 2021 Jun;84(6):407-418.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33533485/)\nGlutsch V, Kneitz H, Gesierich A, Goebeler M, Haferkamp S, Becker JC, Ugurel S, Schilling B (2021)\nActivity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.\nCancer Immunol Immunother. 2021 Jul;70(7):2087-2093.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33439294/)\nHaggenm\u00fcller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, M\u00fcller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fr\u00f6hling S, Hauschild A, Kittler H, Brinker TJ (2021)\nSkin Cancer Classification via Convolutional Neural Networks: Systematic Review of Studies Involving Human Experts.\nEur J Cancer Eur J Cancer 156: 202-216\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/30333097/)\nHamm H, Wilsmann-Theis D, Tsianakas A, Gambichler T, Taipale K, Lauterbach J, Freudensprung U, Makepeace C and KIFUderm study investigators (2021)\nEfficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis - A randomised, double-blinded, placebo-controlled trial.\nBr J Dermatol. 2021 Jul;185(1):62-73.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33332574/)\nHeck J, H Krichevsky B, Krause, O, Goebeler M, Stichtenoth DO, Bleich S, Grohmann R, Dabbert D, Toto S, Seifert J (2021)\nPhotosensibilisierung durch Psycho\u00ac pharmaka und andere Arzneimittel.\nPsychopharmakotherapie 28: 94\u2013101\nZur Publikation\nHeitmann J, Frings VG, Geier A, Goebeler M, Kerstan A (2021)\nNicht-alkoholische Fettlebererkrankung und Psoriasis - besteht ein gemeinsames proinflammatorisches Netzwerk?\nJ Dtsch Dermatol Ges. 2021 Apr;19(4):517-529.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33861000/)\nHeitmann J, Frings VG, Geier A, Goebeler M, Kerstan A (2021)\nNon-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?\nJ Dtsch Dermatol Ges 19: 517-528\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33768700/)\nHodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ (2021)\nCutaneous Lymphoma International Consortium (CLIC) institutions. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.\nBr J Dermatol. 2021 Mar;184(3):524-531.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/32574377/)\nHoesl C, Fr\u00f6hlich T, Posch C, Kneitz H, Goebeler M, Schneider MR, Dahlhoff M (2021)\nThe transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.\nMol Oncol. 2021 Mar 31.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33786987/)\nH\u00f6hn J, Hekler A, Krieghoff-Henning E, Kather JN, Utikal JS, Meier F, Gellrich FF, Hauschild A, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Heppt M, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Maron RC, Schmitt M, Jutzi T, Fr\u00f6hling S, Lipka DB, Brinker TJ (2021)\nIntegrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review.\nJ Med Internet Res. 2021 Jul 2;23(7):e20708.\n[Zur Publikation](https://www.jmir.org/2021/7/e20708)\nH\u00f6hn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, Schlager JG, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Hekler A, Fr\u00f6hling S, Lipka DB, Kather JN, Krahl D, Ferrara G, Haggenm\u00fcller S, Brinker TJ (2021)\nCombining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.\nEur J Cancer. 2021 May;149:94-101\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33838393/)\nIckrath F, Stoevesandt J, Schulmeyer L, Glatzel C, Goebeler M, Kerstan A (2021)\nMetastatischer Morbus Crohn: eine untersch\u00e4tzte Entit\u00e4t.\nJ Dtsch Dermatol Ges. 2021 19(7):973-982.\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14447_g)\nIckrath F, Stoevesandt J, Schulmeyer L, Glatzel C, Goebeler M, Kerstan A (2021)\nMetastatic Crohn's disease: an underestimated entity.\nJ Dtsch Dermatol Ges. 2021 July 19(7):973-982.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33960613/)\nJ\u00e4gle S, Juratli HA, Hickman G, S\u00fcssmuth K, Boente MC, Kopp J, Kirchmeier P, Zimmer A, Happle R, Bourrat E, Hamm H, Fischer J (2021)\nPorokeratosis Plantaris, Palmaris et Disseminata Caused by Con- genital Pathogenic Variants in the MVD Gene and Loss of Hetero-zygosity in Affected Skin.\nActa Derm Venereol. 2021 Feb 16;101(2):\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33491095/)\nKadioglu O, Saeed MEM, Greten HJ, Mayr K, Schrama D, Roos WP, Efferth T (2021)\nIdentification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.\nJ Am Acad Dermatol 2021 Apr;84(4):1086-1089\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/32707252/)\nK\u00e4hler KC, Gutzmer R, Meier F, Zimmer L, Heppt M, Gesierich A, Thoms KM, Utikal J, Hassel JC, Loquai C, Pf\u00f6hler C, Heinzerling L, Kaatz M, G\u00f6ppner D, Pflugfelder A, Bohne AS, Satzger I, Reinhardt L, Placke JM, Schadendorf D, Ugurel S (2021)\nEarly Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.\nFront Oncol. 2021 May 24;11:672172.\n[Zur Publikation](https://www.frontiersin.org/articles/10.3389/fonc.2021.672172/full)\nKempf W, Mitteldorf C, Battistella M, Willemze R, Cerroni L, Santucci M, Geissinger E, Jansen P, Vermeer MH, Marschalko M, Papadavid E, Piris MA, Ortiz-Romero PL, Novelli M, Paulli M, Quaglino P, Ranki A, Rodr\u00edguez Peralto JL, Wobser M, Auschra B, Robson A (2021)\nPrimary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features.\nJ Eur Acad Dermatol Venereol. 2021 Mar;35(3):658-668.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/32997839/)\nKirsten N, Frings V, Nikolakis GD, Presser D, Goebeler M, Zouboulis CC, Augustin M (2021)\nEpidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa.\nHautarzt. (2021) 72:651-657_doi: 10.1007/s00105-021-04851-z\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34223939/)\nKneitz H, Goebeler M, R\u00fctten A (2021)\nNevus sebaceus of the scalp with stepwise progression into invasive syringocystadenocarcinoma papilliferum.\nAm J Dermatopathol (2021, im Druck)\nZur Publikation\nKnispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, K\u00e4hler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA, Drexler K, Pf\u00f6hler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L (2021)\nOutcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.\nEur J Cancer. 2021 May;148:61-75\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33735811/)\nKoch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Hohberger B, K\u00e4hler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pf\u00f6hler C, Rahimi F, Schadendorf D, Schell B, Schlaak M, Terheyden P, Thoms KM, Schuler-Thurner B, Ugurel S, Ulrich J, Utikal J, Weichenthal M, Ziller F, Berking C, Heppt MV, On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma (2021)\nImmune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.\nCancers 13: 3359\n[Zur Publikation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833453/)\nKramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L, Loquai C, Dudda M, Pf\u00f6hler C, Hepner A, Long GV, Menzies AM, Carlino MS, Sachse MM, Lebb\u00e9 C, Baroudjian B, Enokida T, Tahara M, Schlaak M, Hayani K, Br\u00f6ckelmann PJ, Meier F, Reinhardt L, Friedlander P, Eigentler T, K\u00e4hler KC, Berking C, Zimmer L, Heinzerling L (2021)\nHematological immune related adverse events after treatment with immune checkpoint inhibitors.\nEur J Cancer. 2021 Apr;147:170-181.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33706206/)\nLettau K, Khozooei S, Kosnopfel C, Zips D, Schittek B, Toulany M (2021)\nTargeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors.\nInt J Radiat Oncol Biol Phys 111: 1072-1087\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34166770/)\nLodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Ka\u0308hler K, Schilling B, Loquai C, Berking C, Hu\u0308ning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E (2021)\nFactors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.\nCancers 2021, 13, 2319.\n[Zur Publikation](https://www.mdpi.com/2072-6694/13/10/2319)\nMaron RC, Haggenm\u00fcller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hauschild A, French LE, Schlaak M, Ghoreschi K, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Hekler A, Krieghoff-Henning E, Kather JN, Fr\u00f6hling S, Lipka DB, Brinker TJ (2021)\nRobustness of convolutional neural networks in recognition of pigmented skin lesions.\nEur J Cancer. 2021 145:81-91.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33423009/)\nMaron RC, Schlager JG, Haggenm\u00fcller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Heppt MV, Berking C, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Krieghoff-Henning E, Hekler A, Fr\u00f6hling S, Lipka DB, Kather JN, Brinker TJ (2021)\nA Benchmark for Neural Network Robustness in Skin Cancer Classification.\nEur J Cancer 2021 155:191-199\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34388516/)\nMarquardt A, Solimando AG, Kerscher A, Bittrich M, Kalogirou C, K\u00fcbler H, Rosenwald A, Bargou R, Kollmannsberger P, Schilling B, Meierjohann S, Krebs M (2021)\nSubgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.\nFront Oncol. 2021 Mar 15;11:621278.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33791209/)\nMohme S, Goebeler M, Hamm H (2021)\nA child with blistering skin lesions: a crown of jewels.\nEur J Dermatol. 2021 Apr 1;31(2):285-286.\n[Zur Publikation](https://link.springer.com/article/10.1684/ejd.2021.4030)\nMohme S, Goebeler M, Hamm H (2021)\nA blistering child: a toddler with large bullae.\nEur J Dermatol 31: 853-855\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/35107079/)\nMohme S, Alband N, Diaz AR, Lefevre MA, Rodriguez Lomba E, Nogueira M, Goebeler M, Hamm H (2021)\nJournal club: Update on systemic therapies in paediatric dermatology.\nEur J Dermatol 31: 672-675\n[Zur Publikation](https://link.springer.com/article/10.1684/ejd.2021.4152)\nMuhammad K, Xavier D, Klein-Hessling S, Azeem M, Rauschenberger T, Murti K, Avots A, Goebeler M, Klein M, Bopp T, Sielaff M, Tenzer S, M\u00f6ckel S, Aramburu J, L\u00f3pez-Rodr\u00edguez C, Kerstan A, Serfling E (2021)\nNFAT5 Controls the Integrity of Epidermis.\nFront Immunol 12:780727. doi: 10.3389/fimmu.2021.780727\n[Zur Publikation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696207/)\nNicolay JP, Albrecht JD, Assaf C, Dippel E, Stadler R, Wehkamp U, Wobser M, Guelow K, Goerdt S, Krammer PH (2021)\nDimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study.\nEur J Cancer 156 Suppl 1:S21-S22. doi: 10.1016/S0959-8049(21)00666-3.\nZur Publikation\nPaudel R, Fusi L, Schmidt M (2021)\nThe MEK5/ERK5 pathway in health and disease.\nInt J Mol Sci\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34299213/)\nQuaglino P, Prince HM, Cowan R, Vermeer M, Papadavid L, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi \u00c1, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ (2021)\nTreatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study).\nBr J Dermatol. 2021 Apr;184(4):722-730.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/32479678/)\nRogner DF, Lammer J, Zink A, Hamm H (2021)\nMorbus Darier und Morbus Hailey-Hailey: Stand 2021.\nJ Dtsch Dermatol Ges 19: 1478-1502\n[Zur Publikation](https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14619_g)\nRogner DF, Lammer J, Zink A, Hamm H (2021)\nDarier and Hailey-Hailey disease: update 2021.\nJ Dtsch Dermatol Ges 19: 1478-1501\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34661345/)\nSalviano-Silva A, Becker M, Augusto DG, Busch H, Adelman Cipolla G, Farias TDJ, Bumiller-Bini V, Calonga-Sol\u00eds V, Munz M; Franke A, Wittig M, Camargo CM; Goebeler M, Hundt JE, G\u00fcnther C, Gl\u00e4ser R, Hadaschik E, Pf\u00f6hler C, S\u00e1rdy M, van Beek N, Worm M, Zillikens D, Boldt ABW, Schmidt E, Petzl-Erler ML, Ibrahim S, Malheiros D (2021)\nGenetic association and differential expression of HLA Complex Group lncRNAs in pemphigus.\nJ Autoimmunity 123 (2021) 102705\n[Zur Publikation](https://www.sciencedirect.com/science/article/abs/pii/S089684112100113X)\nSalviano-Silva A, Farias TDJ, Bumiller-Bini V, Castro MS, Lobo-Alves SC, Busch H, Pf\u00f6hler C, Worm M, Goebeler M, van Beek N, Franke A, Wittig M, Zillikens D, de Almeida RC, Hundt JE, Boldt ABW, Ibrahim S, Augusto DG, Petzl-Erler ML, Schmidt E, Malheiros D (2021)\nGenetic variability of immune-related lncRNAs: polymorphisms in LINC-PINT and LY86-AS1 are associated with pemphigus foliaceus susceptibility.\nExp Dermatol. 2021 Jan 4. doi: 10.1111/exd.14275\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33394553/)\nSchargus M, Langhorst CA, Joachim S, Frings A, Krause K, Reifenberger J, Geerling G, Frings VG (2021)\nHidradenitis Suppurativa is Associated with Symptoms of Keratoconjunctivitis Sicca.\nCurr Eye Res. 2021 Jan;46(1):23-30.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/32506959/)\nSchmidt M, Mortensen LS, Loeffler-Wirth H, Kosnopfel C, Krohn K, Binder H, Kunz M (2021)\nSingle-cell trajectories of melanoma cell resistance to targeted treatment.\nCancer Biol Med 19: 56-73\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34591417/)\nSchmitt T, Egu DT, Walter E, Sigmund AM, Eichkorn R, Yazdi A, Schmidt E, S\u00e1rdy M, Eming R, Goebeler M, Waschke J (2021)\nCa2+ signalling is critical for autoantibody-induced blistering of human epidermis in pemphigus.\nBr J Dermatol. 2021 Apr 1. doi: 10.1111/bjd.20091.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33792909/)\nSchwarm C, Gola D, Holtsche MM, Dieterich A, Bhandari A, Freitag M, N\u00fcrnberg P, Toliat M, Lieb W, Wittig M, Franke A, Worm M, Sticherling M, Ehrchen J, G\u00fcnther C, Gl\u00e4ser R, Peitsch WK, S\u00e1rdy M, Eming R, Hertl M, Benoit S, Goebeler M, Pf\u00f6hler C, Kunz M, Kreuter A, van Beek N, Erdmann J, Busch H, Zillikens D, Sadik CD, Hirose M, K\u00f6nig IR, Schmidt E, Ibrahim SM; German AIBD Study Group (2021)\nIdentification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans. Orphanet\nJ Rare Dis. 2021 May 19;16(1):228. doi: 10.1186/s13023-021-01863-9\n[Zur Publikation](https://link.springer.com/content/pdf/10.1186/s13023-021-01863-9.pdf)\nSteeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, D\u00fccker P, Dummer R, Emmert S, Elsner P, Enk A, Gebhardt C, Gesierich A, Goebeler M, Goerdt S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel JC, Heinzerling L, K\u00e4hler KC, Kaume KM, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, L\u00f6ffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz RKC, Maul LV, M\u00fcller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pf\u00f6hler C, Posch C, Richtig E, Rompel R, Sachse MM, Sauder S, Schadendorf D, Schatton K, Schulze HJ, Schultz E, Schilling B, Schmuth M, Simon JC, Streit M, Terheyden P, Thiem A, T\u00fcting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) (2021)\nPatterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).\nJ Cancer Res Clin Oncol. 2021 147:1763-1771.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33219855/)\nStege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, Becker JC, Meissner M, Kleeman J, Pf\u00f6hler C, Hassel J, Grabbe S, Loquai C (2021)\nResponse durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.\nCancer Immunol Immunother. 2021 Apr 18. doi: 10.1007/s00262-021-02925-4\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33870464/)\nSturm GJ, Herzog SA, Aberer W, Alfaya Arias T, Antol\u00edn-Am\u00e9rigo D, Bonadonna P, Boni E, Bo\u017cek A, Che\u0142mi\u0144ska M, Ernst B, Frelih N, Gawlik R, Gelincik A, Hawranek T, Hoetzenecker W, Jim\u00e9nez Blanco A, Kita K, Kendirlinan R, Ko\u0161nik M, Laipold K, Lang R, Marchi F, Mauro M, Nittner-Marszalska M, Poziomkowska-G\u0119sicka I, Pravettoni V, Preziosi D, Quercia O, Reider N, Rosiek-Biegus M, Ruiz-Leon B, Schrautzer C, Serrano P, Sin A, Sin BA, Stoevesandt J, Trautmann A, Vachov\u00e1 M, Arzt-Gradwohl L (2021)\n\u03b2-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy.\nAllergy. 2021 Feb 19. doi: 10.1111/all.14785.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33605465/)\nSunderk\u00f6tter C, Wohlrab J, Hamm H (2021)\nEpidemiologie, Diagnostik und Therapie der Skabies.\nDt. \u00c4rzteblatt (2021, im Druck)\nZur Publikation\nThomann AS, Schneider T, Cyran L, Eckert IN, Kerstan A, Lutz MV (2021)\nConversion of Anergic T Cells Into Foxp3- IL-10+ Regulatory T Cells by a Second Antigen Stimulus In Vivo.\nFrontiers Immunol. 25 June 2021 doi: 10.3389/fimmu.2021.704578\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34249012/)\nTorres MJ, Trautmann A, B\u00f6hm I, Scherer K, Barbaud A, Bavbek S, Bonadonna P, Cernadas J, Chiriac A, Gaeta F, Gimenez-Arnau AM, Kang H, Moreno E, Brockow K (2021)\nPractice Parameters for Diagnosing and Managing Iodinated Contrast Media Hypersensitivity.\nAllergy. 2021 May;76(5):1325-1339.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33170954/)\nTraidl S, Werfel T, Ru\u00ebff F, Simon D, Lang C, Geier J; IVDK (u. a. Trautmann A) (2021)\nPatch test results in patients with suspected contact allergy to shoes: Retrospective IVDK data analysis 2009-2018.\nContact Dermatitis 85: 297-306\nZur Publikation\nTrubiano JA, Soria A, Torres MJ, Trautmann A (2021)\nTreating Through of Drug-Associated Exanthem in Drug Allergy Management: Current Evidence and Clinical Aspects.\nJ Allergy Clin Immunol Pract. 2021 Apr 17:S2213-2198(21)00448-7. doi: 10.1016/j.jaip.2021.04.008.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33878455/)\nVersluis JM, Reijers ILM, Rozeman EA, Menzies AM, van Akkooi ACJ, Wouters MW, Ch'ng S, Saw RPM, Scolyer RA, van de Wiel BA, Schilling B, Long GV, Blank CU (2021)\nNeoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.\nEur J Cancer. 2021 May;148:51-57.\n[Zur Publikation](https://www.sciencedirect.com/science/article/abs/pii/S0959804921000952#:~:text=Patients%20with%20synchronous%20clinical%20stage%20III%20melanoma%20can,in%20patients%20with%20nodal%20macroscopic%20stage%20III%20melanoma.)\nWedi B, Aberer W, Brockow K, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, Merk HF, M\u00fclleneisen N, Ott H, Pf\u00fctzner W, R\u00f6seler S, Ru\u00ebff F, Sunderk\u00f6tter C, Trautmann A, Treudler R, Worm M, Wurpts G (2021)\nInduction of penicillin tolerance during pregnancy : Allergological opinion on the recommendation of the current Guidelines on Diagnosis and Treatment of Syphilis (AWMF Registry No. 059-002).\nHautarzt. 2021 Apr;72(4):349-353.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33655345/)\nWedi B, Aberer W, Brockow K, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, Merk HF, M\u00fclleneisen N, Ott H, Pf\u00fctzner W, R\u00f6seler S, Ru\u00ebff F, Sunderk\u00f6tter C, Trautmann A, Treudler R, Worm M, Wurpts G (2021)\nInduction of penicillin tolerance during pregnancy: Allergological opinion on the recommendation of the current AWMF Guidelines on Diagnosis and Treatment of Syphilis (AWMF Registry No. 059-002).\nAllergol Select. 2021 Jan 26;5:67-71.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33521510/)\nWehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, Hillen U, Kempf W, Assaf C (2021)\nMost rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.\nBr J Dermatol. 2021 185, 228-230.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33480069/)\nWessely A, Steeb T, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) (2021)\nSurveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group.\nEur J Cancer. 2021 Jan;143:43-45.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/33279851/)\nWobser M, Roth S, Appenzeller S, Kneitz H, Goebeler M, Geissinger E, Rosenwald A, Maurus K (2021)\nOncogenic mutations and gene fusions in CD30-positive lymphoproliferations and clonally related mycosis fungoides occurring in the same patients.\nJID Innovations (2021) 1:1000034_doi: 10.1016/j.xjidi.2021.100034.\n[Zur Publikation](https://www.jidinnovations.org/article/S2667-0267(21)00034-5/fulltext)\nWobser M, Roth S, Appenzeller S, Houben R, Schrama D, Goebeler M, Geissinger E, Rosenwald A, Maurus K (2021)\nTargeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation.\nCancers 13: 5512.\n[Zur Publikation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582785/)\nZaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, Gutzmer R, Utikal J, Haferkamp S, Reinhardt L, K\u00e4hler KC, Weishaupt C, Moreira A, Thoms KM, Wilhelm T, Pf\u00f6hler C, Roesch A, Ugurel S, Zimmer L, Stadtler N, Sucker A, Kiecker F, Heinzerling L, Meier F, Meiss F, Schlaak M, Schilling B, Horn S, Schadendorf D, Livingstone E (2021)\nClinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.\nEur J Cancer. 2021 Jun 5;152:139-154.\n[Zur Publikation](https://pubmed.ncbi.nlm.nih.gov/34102453/)\nZaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pf\u00f6hler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebb\u00e9 C, Enokida T, Tahara M, Br\u00f6ckelmann PJ, Eigentler T, K\u00e4hler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L (2021)\nGrade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.\nFront Oncol 11:765608\n[Zur Publikation](https://www.frontiersin.org/articles/10.3389/fonc.2021.765608/full)\nPublikationen 2020\nAdam C, Fusi L, Weiss N, Goller SG, Meder K, Frings VG, Kneitz H, Goebeler M, Houben R, Schrama D, Schmidt M (2020)\nEfficient suppression of NRAS-driven melanoma by co-inhibition of ERK1/2 and ERK5 MAPK pathways.\nJ Invest Dermatol. 2020 Dec;140(12):2455-2465\nAmaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L (2020)\nCombined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients.\nJ Immunother Cancer. 2020 Mar,8(1):e000333.\nAzeem M, Kader H, Kerstan A, Hetta HF, Serfling E, Goebeler M, Muhammad K (2020)\nIntricate Relationship Between Adaptive and Innate Immune System in Allergic Contact Dermatitis.\nYale J Biol Med. 2020 Dec 29;93(5):699-709\nBr\u00f6cker EB, Buhl T, Frank J, Fritsch P, Goerdt S, Gollnick HPM, Sch\u00f6n MP (2020)\nWolfram Sterry und das Journal der Deutschen Dermatologischen Gesellschaft - Erinnerung an eine Erfolgsgeschichte in mehreren Akten.\nJ Dtsch Dermatol Ges. 2020 Dec;18(12):1531-1532\nBr\u00f6cker EB (2020)\nEin JDDG-Heft f\u00fcr Peter Fritsch zum 80. Geburtstag.\nJ Dtsch Dermatol Ges. 2020 Nov;18(11):1210.\nBuhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Sch\u00f6n MP, Sticherling M, Sunderk\u00f6tter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M (2020)\nCOVID\u201019 und Auswirkungen auf dermatologische und allergologische Erkrankungen.\nJ Dtsch Dermatol Ges. 2020 Aug;18(8):815-825.\nConway JR, Dietlein F, Taylor-Weiner A, AlDubayan S, Vokes N, Keenan T, Reardon B, He MX, Margolis CA, Weirather JL, Haq R, Schilling B, Stephen Hodi F, Schadendorf D, Liu D, Van Allen EM (2020)\nIntegrated molecular drivers coordinate biological and clinical states in melanoma.\nNat Genet. 2020 Dec;52(12):1373-1383.\nErhard F, D\u00f6lken L, Schilling B, Schlosser A (2020)\nIdentification of the Cryptic HLA-I Immunopeptidome.\nCancer Immunol Res. 2020 Aug;8(8):1018-1026.\nFan K, Gravemeyer J, Ritter C, Rasheed K, Gambichler T, Moens U, Shuda M, Schrama D, Becker JC (2020)\nMCPyV Large T Antigen-Induced Atonal Homolog 1 Is a Lineage-Dependency Oncogene in Merkel Cell Carcinoma.\nJ Invest Dermatol. 2020 Jan;140(1):56-65.e3.\nFan K, Zebisch A, Horny K, Schrama D, Becker JC (2020)\nHighly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma.\nCancers (Basel). 12(3):529.\nFan K, Zebisch A, Horny K, Schrama D, Becker JC (2020)\nHighly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma.\nCancers (Basel). 2020 Feb 25;12(3):529.\nFrings VG, Goebeler M, Kneitz H (2020)\nDermpath & Clinic: Where the shoe pinches - painful plantar plaque.\nEur J Dermatol. 2020 Aug 1;30(4):447-449.\nFrings VG, Goebeler M, Kneitz H (2020)\nDermpath & Clinic: Too many irons in the fire.\nEur J Dermatol. 2020 Oct 1;30(5):624-625\nGarbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderk\u00f6tter C, T\u00fcting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer (2020)\nPrognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.\nJ Clin Oncol. 2020 Aug 1;38(22):2543-2551.\nGlutsch V, Amaral T, Garbe C, Thoms KM, Mohr P, Hauschild A, Schilling B (2020)\nIndirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.\nActa Derm Venereol. 2020 Jun 11;100(13):adv00174\nGr\u00e4n F, Kerstan A, Serfling E, Goebeler M, Muhammad K (2020)\nCurrent Developments in the Immunology of Psoriasis.\nYale J Biol Med. 93(1):97-110.\nGr\u00e4n F, Emmerich K, Mohme S, Goebeler M, Gesierich A (2020)\nVitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.\nEur J Dermatol. 30(1):72-73.\nHaeger A, Alexander S, Vullings M, Kaiser FMP, Veelken C, Flucke U, Koehl GE, Hirschberg M, Flentje M, Hoffman RM, Geissler EK, Kissler S, Friedl P (2020)\nCollective cancer invasion forms an integrin-dependent radioresistant niche.\nJ Exp Med. 2020 Jan 6,217(1). 217(1):e20181184.\nHaferkamp S, Alter M, Debus D, Schilling B, Pinter A, Terheyden P, Utikal JS, Sachse MM, Haalck T, Wolf IH (2020)\nPatients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice.\nAdv Ther. 2020 Aug;37(8):3619-3629\nHekler A, Kather JN, Krieghoff-Henning E, Utikal JS, Meier F, Gellrich FF, Upmeier Zu Belzen J, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Berking C, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Izar B, Maron R, Schmitt M, Fr\u00f6hling S, Lipka DB, Brinker TJ (2020)\nEffects of Label Noise on Deep Learning-Based Skin Cancer Classification.\nFront Med (Lausanne). 2020 May 6,7:177.\nHeck J, Olk J, Kneitz H, Hamm H, Goebeler M (2020)\nLong-standing morphea and the risk of squamous cell carcinoma of the skin.\nJ Dtsch Dermatol Ges. 2020 Jul,18(7):669-673.\nHosp C, Benoit S, Goebeler M, Stoevesandt J (2020)\nRituximab-mediated late onset neutropenia in autoimmune blistering diseases: negligible or under-estimated threat?\nJ Dtsch Dermatol Ges. 2020 Oct,18(10):1162-1164.\nHouben R, Ebert M, Hesbacher S, Kervarrec T, Schrama D (2020)\nMerkel Cell Polyomavirus Large T Antigen is Dispensable in G2 and M-Phase to Promote Proliferation of Merkel Cell Carcinoma Cells.\nViruses. 2020 Oct 14;12(10):1162.\nJessen C, Kre\u00df JKC, Baluapuri A, Hufnagel A, Schmitz W, Kneitz S, Roth S, Marquardt A, Appenzeller S, Ade CP, Glutsch V, Wobser M, Friedmann-Angeli JP, Mosteo L, Goding CR, Schilling B, Geissinger E, Wolf E, Meierjohann S (2020)\nThe transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.\nOncogene. 2020 Oct;39(44):6841-6855.\nJoly P, Horvath B, Patsatsi \u0391, Uzun S, Bech R, Beissert S, Bergman R, Bernard P, Borradori L, Caproni M, Caux F, Cianchini G, Daneshpazhooh M, De D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Guenther C, Hofmann S, Ioannides D, Kowalewski C, Ludwig R, Lim YL, Marinovic B, Marzano AV, Mascar\u00f3 JM Jr, Mimouni D, Murrell DF, Pincelli C, Squarcioni CP, S\u00e1rdy M, Setterfield J, Sprecher E, Vassileva S, Wozniak K, Yayli S, Zambruno G, Zillikens D, Hertl M, Schmidt E (2020)\nUpdated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).\nJ Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-1913\nKervarrec T, Zaragoza J, Gaboriaud P, Berthon P, Fromont G, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Michenet P, Maillard H, Houben R, Schrama D, Caille A, Touz\u00e9 A, Guy\u00e9tant S, Samimi M (2020, online ahead of print)\nMerkel cell carcinoma of lymph nodes without a skin primary tumor: a potential metastatic neoplasia associated with a brisk immune response.\nJ Am Acad Dermatol. S0190-9622(20)30535-1. doi: 10.1016/j.jaad.2020.03.108.\nKervarrec T, Aljundi M, Appenzeller S, Samimi M, Maubec E, Cribier B, Deschamps L, Sarma B, Sarosi EM, Berthon P, Levy A, Bousquet G, Tallet A, Touz\u00e9 A, Guy\u00e9tant S, Schrama D, Houben R (2020)\nPolyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma.\nJ Invest Dermatol. 140(5):976-985.\nKervarrec T, Tallegas M, Schrama D, Houben R, Ollier J, Cl\u00e9menceau B, Vi\u00e9 H, Touz\u00e9 A, Samimi M, Guy\u00e9tant S (2020)\nBerEP4 positivity in Merkel cell carcinoma: a potential diagnosis pitfall.\nJ Eur Acad Dermatol Venereol. doi: 10.1111/jdv.16482.\nKnispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, Pf\u00f6hler C, Gesierich A, Herbst R, Kaehler KC, Weide B, Berking C, Loquai C, Utikal J, Terheyden P, Kaatz M, Schlaak M, Kreuter A, Ulrich J, Mohr P, Dippel E, Livingstone E, Becker JC, Weichenthal M, Chorti E, Gronewold J, Schadendorf D, Ugurel S (2020)\nImpact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.\nJ Immunother Cancer. (1):e000395.\nKosnopfel C, Sinnberg T, Sauer B, Niessner H, Muenchow A, Fehrenbacher B, Schaller M, Mertens PR, Garbe C, Thakur BK, Schittek B (2020)\nTumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion.\nCancers (Basel). 2020 Aug 18;12(8):2328. doi: 10.3390/cancers12082328\nKrebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S, Bargou R, K\u00fcbler H, Schilling B, Spahn M, Kneitz B (2020)\nmiR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro.\nJ Clin Med. 2020 Mar 2;9(3):670.\nKroi\u00df M, Schilling B, Deutschbein T (2020)\nEndocrine side effects of cancer immunotherapy.\nDtsch Med Wochenschr. 2020 Dec;145(24):1736-1741.\nLeiter U, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, Hassel JC, Glutsch V, Sirokay J, Schlecht N, R\u00fcbben A, Gambichler T, Schatton K, Pfoehler C, Franklin C, Terheyden P, Haferkamp S, Mohr P, Bischof L, Livingstone E, Zimmer L, Weichenthal M, Schadendorf D, Meiwes A, Keim U, Garbe C, Becker JC, Ugurel S (2020)\nImmune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.\nJ Immunother Cancer. 2020 Oct;8(2):e000897. doi: 10.1136/jitc-2020-000897.\nLivingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG (2020)\nGNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.\nBr J Dermatol. 2020 Nov;183(5):928-939.\nMaurus K, Appenzeller S, Roth S, Br\u00e4ndlein S, Kneitz H, Goebeler M, Rosenwald A, Geissinger E, Wobser M (2020)\nRecurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders.\nJ Invest Dermatol. 2020 Oct;140(10):2023-2031.\nMaron RC, Utikal JS, Hekler A, Hauschild A, Sattler E, Sondermann W, Haferkamp S, Schilling B, Heppt MV, Jansen P, Reinholz M, Franklin C, Schmitt L, Hartmann D, Krieghoff-Henning E, Schmitt M, Weichenthal M, von Kalle C, Fr\u00f6hling S, Brinker TJ (2020)\nArtificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study.\nJ Med Internet Res. 2020 Sep 11;22(9):e18091.\nMayser P, Nenoff P, Reinel D, Abeck D, Brasch J, Daeschlein G, Effendy I, Ginter-Hanselmayer G, Gr\u00e4ser Y, Hipler UC, H\u00f6ger P, Kolb-M\u00e4urer A, Ott H, Schaller M, Zidane M (2020)\nS1-Leitlinie Tinea capitis.\nJ Dtsch Dermatol Ges. 2020 Feb;18(2):161-180.\nMichielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebb\u00e9 C, Lugowska I, Mandal\u00e0 M, M\u00e1rquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U (2020)\nESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.\nAnn Oncol. 2020 Nov;31(11):1449-1461.\nMohme S, Schmalzing M, Mu\u0308ller CSL, Vogt T, Goebeler M, Stoevesandt J (2020)\nImpfen bei Immunsuppression: ein Leitfaden fu\u0308r die dermatologische Praxis.\nJ Dtsch Dermatol Ges. 2020 Jul;18(7):699-725.\nMolloy K, Jonak C, Woei-A-Jin FJSH, Guenova E, Busschots AM, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, Cowan R, Papadavid E, Beylot-Barry M, Berti E, Alberti Violetti S, Estrach T, Matin R, Akilov O, Vakeva L, Prince M, Bates A, Bayne M, Wachsmuch R, Wehkamp U, Marschalko M, Servitje O, Turner D, Weatherhead S, Wobser M, Sanches JA, McKay P, Klemke D, Peng C, Howles A, Yoo J, Evison F, Scarisbrick J (2020)\nCharacteristics associated with significantly worse quality of life in mycosis fungoides/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020 Mar;182(3):770-779.\nOrouji E, Peitsch WK, Orouji A, Houben R, Utikal J (2020)\nUnique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.\nCancers (Basel). 2020 Apr 24;12(4):E1057.\nOrouji E, Peitsch WK, Orouji A, Houben R, Utikal J (2020)\nOncogenic Role of an Epigenetic Reader of m6A RNA Modification: YTHDF1 in Merkel Cell Carcinoma.\nCancers (Basel). 2020 Jan 14;12(1):202.\nReichel A, Grothaus J, Ott H (2020)\nPityriasis lichenoides acuta (PLEVA) pemphigoides: A rare bullous variant of PLEVA.\nPediatr Dermatol. 2020 Jul;37(4):710-712.\nReichel A, R\u00f6ding K, Stoevesandt J, Trautmann A(2020)\nDe-labelling antibiotic allergy through five key questions.\nClin Exp Allergy. 2020 Apr;50(4):532-535.\nRongisch R, Schmidt E, Deresz N, Deresz K, Sch\u00f6fer H, Sch\u00e4kel K, Jakob T, Maurer M, Sticherling M, Sunderk\u00f6tter C, Babilas P, Spornraft-Ragaller P, Traidl-Hoffmann C, Gl\u00e4ser R, Hartmann K, Kolb-M\u00e4urer A, Wenzel J, Biedermann T, Homey B, Pf\u00fctzner W, Weid F, Fischer M, Linder R, von Stebut E (2020)\nTravel-associated infectious skin diseases.\nJ Dtsch Dermatol Ges. 2020 Jul;18(7):730-733.\nSarma B, Willmes C, Angerer L, Adam C, Becker JC, Kervarrec T, Schrama D, Houben R (2020)\nArtesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma.\nCancers (Basel). 2020; Apr 9;12(4):E919.\nSchargus M, Br\u00fcckner KA, Frings VG, Frings A (2020)\nBilateral conjunctival chemosis.\nOphthalmologe. 2020 Feb;117(2):154-157.doi: 10.1007/s00347-019-00960-2.\nSchlegel S, Hamm H, Reichel A, Kneitz H, Ernestus K, Andres O, Wiegering VG, Eyrich M, W\u00f6lfl M, Schlegel PG (2020)\nNeonatal Acute Lymphoblastic Leukemia with t(9;11) Translocation Presenting as Blueberry Muffin Baby: Successful Treatment by ALL-BFM Induction Therapy, Allogeneic Stem Cell Transplantation from an Unrelated Donor, and PCR-MRD-Guided Post-Transplant Follow-Up.\nAm J Case Rep. 2020 Oct 27;21:e927153\nSchmidt E, Sticherling M, S\u00e1rdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski HD, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M (2020)\nS2k guidelines for the treatment of pemphigus vulgaris/ foliaceus and bullous pemphigoid: 2019 update.\nJ Deutsch Dermatol Ges 2020 May; 18:516-526.\nSchnuch A, Schubert S, Lessmann H, Geier J; IVDK (2020)\nThe methylisothiazolinone epidemic goes along with changing patients' characteristics - After cosmetics, industrial applications are the focus.\nContact Dermatitis. 2020 Feb;82(2):87-93.\nSch\u00f6n MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Sch\u00e4kel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K (2020)\nCOVID\u201019 und Immunregulation \u2013 von grundlegenden und translationalen Aspekten zu klinischen Implikationen.\nJ Dtsch Dermatol Ges. 2020 Aug;18(8):795-809\nSchr\u00fcfer P, Brockow K, Stoevesandt J, Trautmann A (2020)\nPredominant patterns of \u03b2-lactam hypersensitivity in a single German Allergy Center: exanthem induced by aminopenicillins, anaphylaxis by cephalosporins.\nAllergy Asthma Clin Immunol. 2020 Nov 17;16(1):102.\nSchummer P, Schilling B, Gesierich A (2020)\nLong-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?\nAm J Clin Dermatol. 2020 Aug;21(4):493-504.\nSpassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, Kubat L, Habermann D, Farahpour F, Saeedghalati M, Peiffer L, Kumar R, Schrama D, Hoffmann D, Schadendorf D, Becker JC (2020)\nPredominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.\nClin Cancer Res. 2020 May 1;26(9):2257-2267.\nStoevesandt J, Sturm GJ, Bonadonna P, Oude Elberink JNG, Trautmann A (2020)\nRisk factors and indicators of severe systemic insect sting reactions.\nAllergy. 2020 Mar; 75(3): 535-545.doi: 10.1111/all.13945.\nStoevesandt J, Heitmann J, Goebeler M, Benoit S (2020)\nNeutropenia resulting from high-dose intravenous immunoglobulin in dermatological patients.\nJ Dtsch Dermatol Ges. 2020 Dec;18(12):1394-1403.\nTrautmann A, Brockow K, Stoevesandt J (2020)\nMetamizole-induced reactions as a paradigm of drug hypersensitivity: Non-allergic reactions, anaphylaxis, and delayed-type allergy.\nClin Exp Allergy. 2020 Sep;50(9):1103-1106.\nUeberschaar S, Goebeler M, Kneitz H (2020)\nCD10-Positive Cutaneous PEComa: An Extremely Rare Skin Tumour.\nCase Rep Dermatol. 2020 Nov 2;12(3):192-198\nUgurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, Pf\u00f6hler C, Herbst R, Schilling B, Blank C, Becker JC, Paschen A, Zimmer L, Livingstone E, Horn PA, Rebmann V (2020)\nElevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.\nAnn Oncol. 2020 Jan;31(1):144-152.\nVilas Boas P, Frings V, Gran F, Lesort C, Machado \u00c1, Arianayagam S (2020)\nWhat's new this month?\nEur J Dermatol. 2020 Apr 1;30(2):210-211.\nWallstabe J, Bussemer L, Groeber-Becker F, Freund L, Alb M, Dragan M, Waaga-Gasser AM, Jakubietz R, Kneitz H, Rosenwald A, Rebhan S, Walles H, Mielke S (2020) Inflammation-induced tissue damage mimicking GvHD in human skin models as test-platform for immunotherapeutics.\nALTEX. 2020;37(3):429-440.\nWeber J, Glutsch V, Geissinger E, Haug L, Lock JF, Schneider F, Kneitz H, Goebeler M, Schilling B, Gesierich A (2020)\nNeoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.\nBr J Dermatol. 2020 Sep;183(3):559-563.\nWestphalen BC, Bokemeyer C, B\u00fcttner R, Fr\u00f6hling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2020)\nConceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group \u2018Molecular Diagnostics and Therapy\u2019.\nEur J Cancer (2020) 135:1-7.\nWobser M, Goebeler M (2020)\nCutaneous lymphomas : Clinical presentation - diagnosis - treatment.\nPathologe. 2020 Feb;41(1):79-94.\nWorm M, Ballmer-Weber B, Brehler R, Cuevas M, Gschwend A, Hartmann K, Hawranek T, H\u00f6tzenecker W, Homey B, Jakob T, Novak N, Pickert J, Saloga J, Sch\u00e4kel K, Trautmann A, Treudler R, Wedi B, Sturm G, Rueff F (2020)\nVersorgungssituation von Insektengiftallergikern w\u00e4hrend der COVID-19-Pandemie.\nAllergo J. 2020;29(8):16-21\nWorm M, Ballmer-Weber B, Brehler R, Cuevas M, Gschwend A, Hartmann K, Hawranek T, H\u00f6tzenecker W, Homey B, Jakob T, Novak N, Pickert J, Saloga J, Sch\u00e4kel K, Trautmann A, Treudler R, Wedi B, Sturm G, Rueff F (2020)\nHealthcare provision for insect venom allergy patients during the COVID-19 pandemic.\nAllergo J Int. 2020;29(8):257-261.\nWurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, Merk HF, M\u00fclleneisen N, Ott H, Pf\u00fctzner W, R\u00f6seler S, Ru\u00ebff F, Sitter H, Sunderk\u00f6tter C, Trautmann A, Treudler R, Wedi B, Worm M, Brockow K (2020)\nGuideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (\u00d6GAI), and the Paul-Ehrlich Society for Chemotherapy (PEG).\nAllergol Select. 2020 May 28;4:11-43.\nZimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, R\u00f6sch A, Simon JC, Conrad B, K\u00f6rner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D on behalf of the Dermatologic Cooperative Oncology Group (2020)\nAdjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.\nLancet. 2020; 395(10236):1558-1568.\nPublikationen 2019\nAlmanzar G, Schmalzing M, Klein M, Hilligardt D, Morris P, H\u00f6fner K, Hajj NE, Kneitz H, Wild V, Rosenwald A, Benoit S, Hamm H, Tony HP, Haaf T, Goebeler M, Prelog M (2019)\nMemory CD4+ T cells lacking expression of CCR7 promote pro-inflammatory cytokine production in patients with diffuse cutaneous systemic sclerosis.\nEur J Dermatol. 29(5):468-476.\nAppenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald R, Schartl M, Goebeler M, Meierjohann S (2019)\nIdentification of patient-specific mutations reveals dual pathway activation in most melanoma patients and activated receptor tyrosine kinases in BRAF/NRAS wildtype melanomas.\nCancer 2019;125, 586-600.\nBallin N, Hotz A, Bourrat E, K\u00fcsel J, Oji V, Bouadjar B, Brognoli D, Hickman G, Heinz L, Vabres P, Marrakchi S, Leclerc-Mercier S, Irvine A, Tadini G, Hamm H, Has C, Blume-Peytavi U, Mitter D, Reitenbach M, Hausser I, Zimmer AD, Alter S, Fischer J (2019)\nGenetical, clinical, and functional analysis of a large international cohort of patients with autosomal recessive congenital ichthyosis due to mutations in NIPAL4.\nHum Mutat. 40(12):2318-2333.\nBoas PV, Arianayagam S, Machado \u00c1CDS, Gran F, Lesort C, Frings V (2019)\nWhat's new this month?\nEur J Dermatol. 29(2):238-239.\nBrinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fr\u00f6hling S, Schilling B, Utikal JS (2019)\nDeep neural networks are superior to dermatologists in melanoma image classification.\nEur J Cancer. 119:11-17.\nBrinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C (2019)\nCollaborators. Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.\nEur J Cancer. 113:47-54.\nBrinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fr\u00f6hling S, Utikal JS, von Kalle C (2019)\nCollaborators. A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.\nEur J Cancer. 111:148-154.\nBrinker TJ, Hekler A, Hauschild A, Berking C, Schilling B, Enk AH, Haferkamp S, Karoglan A, von Kalle C, Weichenthal M, Sattler E, Schadendorf D, Gaiser MR, Klode J, Utikal JS (2019)\nComparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.\nEur J Cancer. 111:30-37.\nDa Silva Machado \u00c1C, Vilas Boas P, Arianayagam S, Gran F, Lesort C, Frings V (2019)\nWhat's new this month?\nEur J Dermatol. 29(3):345-346.\nEisert L, Augustin M, Bach S, Dittmann M, Eiler R, F\u00f6lster-Holst R, Gerdes S, Hamm H, H\u00f6ger P, Horneff G, von Kiedrowski R, Philipp S, Pleimes M, Schlaeger M, Schuster V, Staubach P, Weberschock T, Werner RN, Nast A, Sticherling M (2019)\nS2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 2.\nJ Dtsch Dermatol Ges. 17(9):959-974.\nEisert L, Augustin M, Bach S, Dittmann M, Eiler R, F\u00f6lster-Holst R, Gerdes S, Hamm H, H\u00f6ger P, Horneff G, von Kiedrowski R, Philipp S, Pleimes M, Schlaeger M, Schuster V, Staubach P, Weberschock T, Werner RN, Nast A, Sticherling M (2019)\nS2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 1.\nJ Dtsch Dermatol Ges. 17(8):856-870.\nEmmerich K, Kolb-M\u00e4urer A, Goebeler M. Kutane (2019)\nNichttuberkulo\u0308se Mykobakteriosen.\nAkt Dermatol. 2019;45, 47-5.\nFelcht M, Klemke CD, Nicolay JP, Weiss C, Assaf C, Wobser M, Schlaak M, Hillen U, Moritz R, Tantcheva-Poor I, Nashan D, Beyer M, Dippel E, M\u00fcller CSL, Sachse MM, Meiss F, G\u00e9raud C, Marx A, Goerdt S, Geissinger E, Kempf W (2019)\nPrim\u00e4r kutanes diffus-gro\u00dfzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede.\nJ Dtsch Dermatol Ges. 17(3):275-286.\nFranklin C, Bruderek K, Schilling B, Brandau S (2019)\nChemoirradiated neutrophils and T cells differentially affect immune functions of APCs.\nJ Leukoc Biol. 106(2):481-493.\nFrings VG, M\u00fcller D, Storz G, Rossi A, Sennefelder H, Adam C, Goebeler M, Groeber-Becker FK, Schmidt M (2019)\nImproved metal allergen reactivity of artificial skin models by integration of Toll-like receptor 4-positive cells.\nContact Dermatitis. 81(4):254-261.\nFrings VG, Goebeler M, Kneitz H. Dermpath (2019)\nClinic: Multiple nodules in the axillae: is it that old chestnut Hidradenitis suppurativa again?\nEur J Dermatol. 29(5):569-570.\nFrings VG, Goebeler M, Kneitz H (2019)\nDermPath: Disseminated papules on the upper body: a diagnostic challenge.\nEur J Dermatol. 29(3):346-347.\nFrings VG, Bauer B, Gl\u00f6ditzsch M, Goebeler M, Presser D (2019)\nAssessing the psychological burden of patients with hidradenitis suppurativa.\nEur J Dermatol. 2019;29(3):294-301.\nFrings VG, Sennefelder H, Presser D, Goebeler M, Schmidt M (2019)\nAltered NOX expression does not seem to account for epidermal NLRP3 inflammasome activation in Hidradenitis Suppurativa.\nBr J Dermatol. 181(2):391-392.\nGaffal E, Eming R, Fabri M, Gebhardt C, Stary G, Eyerich S, H\u00f6lzel M, Kosnopfel C, Neubert E, Rauer D, Rodr\u00edguez E, Thiem A, von Meyenn L, Buhl T (2019)\n46th annual congress of the \"Arbeitsgemeinschaft Dermatologische Forschung\" in Munich, Germany.\nExp Dermatol. 28(9):1094-1099.\nGassenmaier M, Keim U, Leiter U, Eigentler TK, R\u00f6cken M, Gesierich A, Moritz RKC, Heinzerling L, T\u00fcting T, Wollina U, Garbe C (2019)\nAge as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry.\nJ Am Acad Dermatol. 80(5):1299-1307.e7.\nGiehl K, Hamm H, Has C (2019)\nRole of the dermatologist in recognizing syndromes.\nHautarzt. 70(7):472-473.\nGiner T, Benoit S, Goebeler M (2019)\nDie Sarkoidose aus dermatologischer Perspektive.\nAkt Dermatol. 2019;45, 40-46.\nGlutsch V, Hamm H, Goebeler M (2019)\nZinkmangeldermatosen.\nJ Dtsch Dermatol Ges. 2019;17(6):589-596.\nGlutsch V, Kneitz H, Goebeler M, Gesierich A, Schilling B (2019)\nBreaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?\nAnn Oncol. 2019 Oct 1;30(10):1667-1668.\nGlutsch V, Gr\u00e4n F, Weber J, Gesierich A, Goebeler M, Schilling B (2019)\nResponse to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.\nJ Immunother Cancer. 7(1):181.\nGoebeler M (2019)\nUniversita\u0308re Dermatologie, Venerologie und Allergologie in Wu\u0308rzburg: Tradition und Innovation.\nAkt Dermatol. 2019;45, 5-6.\nGr\u00e4n F, Arianayagam S, Lesort C, Machado \u00c1, Vilas Boas P, Frings VG (2019)\nWhat's new this month?\nEur J Dermatol. 29(4):446-447.\nGr\u00e4n F, Goebeler M, Gesierich A (2019)\nBullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.\nEur J Dermatol. 29(4):448-449.\nGr\u00e4n F, Goebeler M, Gesierich A (2019). Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors. Eur J Dermatol. 29(1):107-108.\nHamm H, Emmerich K, Olk J (2019)\nPigmented macules as possible early signs of genetic syndromes.\nHautarzt. 70(7):506-513.\nHamm H, Stoevesandt J, Sunderk\u00f6tter C (2019)\nScabies in old age.\nZ Gerontol Geriatr. 52(8):795-807.\nHeitmann J, Houben R, Schrama D, Goebeler M, Gesierich A, Schilling B (2019)\nDas Merkelzellkarzinom: A\u0308tiopathogenese und Management.\nAkt Dermatol 45, 60-66.\nHekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, Haferkamp S, Klode J, Schadendorf D, Schilling B, Holland-Letz T, Izar B, von Kalle C, Fr\u00f6hling S, Brinker TJ (2019)\nCollaborators. Superior skin cancer classification by the combination of human and artificial intelligence.\nEur J Cancer. 120:114-121.\nHeppt MV, Amaral T, K\u00e4hler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pf\u00f6hler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C (2019)\nCombined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.\nJ Immunother Cancer. 7(1):299.\nHerz C, Wobser M, Fischer J, Hamm H. (2019)\nPachyonychia congenita und Steatocystoma multiplex durch Mutation im Keratin-17- Gen.\nAkt Dermatol. 2019;45, 67-71.\nHoesl C, Fr\u00f6hlich T, Hundt JE, Kneitz H, Goebeler M, Wolf R, Schneider MR, Dahlhoff M (2019)\nThe transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis.\nMol Oncol. 13(11):2476-2492.\nIckrath F, Hosp C, Stolze I, Goebeler M, Trautmann A, Kerstan A (2019)\nSuccessful treatment of progressive mucinous histiocytosis with multilayer CO2 laser ablation.\nJ Eur Acad Derm Venereol. 2019 Jul;33(7):e261-e262\nKahlert K, Hamm H, Goebeler M, Kerstan A (2019)\nPityriasis rubra pilaris \u2013 eine seltene entzu\u0308ndliche Dermatose mit vielen Facetten.\nAkt Dermatol. 45, 32-39.\nKahlert K, Gr\u00e4n F, Muhammad K, Benoit S, Serfling E, Goebeler M, Kerstan A (2019)\nAberrant B cell subsets and immunoglobulin levels in patients with moderate-to-severe psoriasis.\nActa Derm Venereol. 2019;99(2):226-227.\nKervarrec T, Gaboriaud P, Tallet A, Leblond V, Arnorld F, Berthon P, Schweinitzer S, Larcher T, Guy\u00e9tant S, Schrama D, Houben R, Samimi M, Touz\u00e9 A (2019)\nVEGF-A inhibition as a potential therapeutic approach in Merkel cell carcinoma.\nJ Invest Dermatol. 2019;139(3):736-739.\nKervarrec T, Tallet A, Miquelestorena-Standley E, Houben R, Schrama D, Gambichler T, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Tabareau-Delalande F, Beneton N, Fromont G, Arbion F, Leteurtre E, Touz\u00e9 A, Samimi M, Guy\u00e9tant S (2019)\nDiagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas.\nMod Pathol. 2019;32(4):499-510.\nKervarrec T, Samimi M, Guy\u00e9tant S, Sarma B, Ch\u00e9ret J, Blanchard E, Berthon P, Schrama D, Houben R, Touz\u00e9 A (2019)\nHistogenesis of Merkel Cell Carcinoma: A Comprehensive Review.\nFront Oncol. 2019;9:451.\nKervarrec T, Tallet A, Miquelestorena-Standley E, Houben R, Schrama D, Gambichler T, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Tabareau-Delalande F, Beneton N, Fromont G, Arbion F, Leteurtre E, Herfs M, Touz\u00e9 A, Samimi M, Guy\u00e9tant S (2019)\nMorphologic and immunophenotypical features distinguishing Merkel cell polyomavirus-positive and negative Merkel cell carcinoma.\nMod Pathol. 2019;32(11):1605-1616.\nKolb-M\u00e4urer A, Sunderk\u00f6tter C, Kukowski B, Meuth SG members of an expert meeting (2019)\nAn update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.\nBMC Neurol. 2019;19(1):130.\nKrebs M, Behrmann C, Kalogirou C, Sokolakis I, Kneitz S, Kruithof-de Julio M, Zoni E, Rech A, Schilling B, K\u00fcbler H, Spahn M, Kneitz B (2019)\nmiR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.\nBiomed Res Int. 2019 Nov;2019:6392748.\nKreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B (2019)\nEfficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.\nEur J Cancer. 2019;116:207-215.\nLesort C, Gr\u00e4n F, Arianayagam S, Machado \u00c1, Vilas Boas P, Frings VG (2019)\nWhat's new this month?\nEur J Dermatol. 2019;29(5):568-569.\nLiu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D (2019)\nIntegrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.\nNat Med. 2019;25(12):1916-1927.\nMaron RC, Weichenthal M, Utikal JS, Hekler A, Berking C, Hauschild A, Enk AH, Haferkamp S, Klode J, Schadendorf D, Jansen P, Holland-Letz T, Schilling B, von Kalle C, Fr\u00f6hling S, Gaiser MR, Hartmann D, Gesierich A, K\u00e4hler KC, Wehkamp U, Karoglan A, B\u00e4r C, Brinker TJ (2019)\nCollaborators. Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.\nEur J Cancer. 2019;119:57-65.\nMenzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pf\u00f6hler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC (2019)\nTargeted Therapy in Advanced Melanoma With Rare BRAF Mutations.\nJ Clin Oncol. 2019;37(33):3142-3151.\nMicoss\u00e9 C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, Morteza Seyed Jafari S, Olah P, Yawlkar N, Simon D, Borradori L, Kuchen S, Yerly D, Homey B, Conrad C, Snijder B, Schmidt M, Schlapbach C (2019)\nHuman \u201cTH9\u201d cells are a subpopulation of PPAR-+ TH2 cells.\nSci Immunol. 2019;4(31). pii: eaat5943. doi: 10.1126/sciimmunol.aat5943.\nMock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schr\u00f6ck E, Brors B, Stenzinger A, J\u00e4ger D, Schlenk R, Glimm H, Fr\u00f6hling S, Horak P (2019)\nDKTK MASTER Network. Community-driven development of a modified progression-free survival ratio for precision oncology.\nESMO Open. 2019 Nov 13;4(6):e000583.\nNothhaft M, Klepper J, Kneitz H, Meyer T, Hamm H, Morbach H (2019)\nHemorrhagic Bullous Henoch-Sch\u00f6nlein Purpura: Case Report and Review of the Literature.\nFront Pediatr. 2019; Jan 22:6:413.\nOlk J, Hamm H, Bro\u0308cker EB, Goebeler M (2019)\nKlinik f\u00fcr Dermatologie, Venerologie und Allergologie des Universita\u0308ts- klinikums Wu\u0308rzburg: Geschichte und Gegenwart.\nAkt Dermatol. (2019) 45, 14-23.\nPersa OD, Loquai C, Wobser M, Baltaci M, Dengler S, Kreuter A, Volz A, Laimer M, Emberger M, Doerler M, Mauch C, Helbig D (2019)\nExtended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas.\nJ Eur Acad Dermatol Venereol. 2019;33(8):1577-1580.\nPiperno-Neumann S, Piulats JM, Goebeler M, Galloway I, Lugowska I, Becker JC, VihinenP, Van Calster J, Hadjistilianou T, Proen\u00e7a R, Caminal JM, Rogasik M, Blay JY, Kapiteijn E (2019)\nUveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer.\nCancers (Basel). 2019;11(6).\nRauschenberger T, Schmitt V, Azeem M, Klein-Hessling S, Murti K, Gr\u00e4n F, Goebeler M, Kerstan A, Klein M, Bopp T, Serfling E, Muhammad K (2019)\nT Cells Control Chemokine Secretion by Keratinocytes.\nFront Immunol. 2019;10:1917.\nR\u00f6ding K, Schru\u0308fer P, Gra\u0308n F, Olk J, Ueberschaar S, Behle V, Kneitz H, Goebeler M, Wobser M. (2019)\nKutane Lymphome \u2013 ein viel- gestaltiges Krankheitsbild.\nAkt Dermatol. 2019;45, 52-59.\nRusslies J, F\u00e4hnrich A, Witte M, Yin J, Benoit S, Gl\u00e4ser R, G\u00fcnter C, Eming R, Erdmann J, Gola D, Gupta Y, Holtsche MM, Kern JS, K\u00f6nig IR, Kiritsi D, Lieb W, Sadik CD, S\u00e1rdy M, Schauer F, van Beek N, Weidinger A, Worm M, Zillikens D, Schmidt E, Busch H, Ibrahim SM, Hirose M (2019)\nPolymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans.\nFront Immunol. 2019;10:2200. doi: 10.3389/fimmu.2019.02200.\nS\u00e1nchez-Borges M, Aberer W, Brockow K, Celik GE, Cernadas J, Greenberger PA, Masse MS, Schrijvers R, Trautmann A (2019)\nControversies in Drug Allergy: Radiographic Contrast Media.\nJ Allergy Clin Immunol Pract. 2019;7, 61-65.\nScarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. (2019)\nThe PROCLIPI international registry of early stage Mycosis Fungoides identifies substantial diagnostic delay in most patients.\nBr J Dermatol. 2019;181(2):350-357.\nSchilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, K\u00e4hler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B (2019)\nFirst-line therapy-stratified survival in BRAF-mutant melanoma: A retrospective multicenter analysis.\nCancer Immunol Immunother. 2019;68(5):765-772.\nSchilling B, Wiesner T (2019)\nTackling melanoma by adjuvant therapy: why, whom and how?\nBr J Dermatol. 2019;180, 1-2.\nSchrama D, Sarosi EM, Adam C, Ritter C, Kaemmerer U, Klopocki E, K\u00f6nig EM, Utikal J, Becker JC, Houben R (2019)\nCharacterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration.\nInt J Cancer. 2019 Aug 15; 145(4):1020-1032.\nSondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fr\u00f6hling S, von Kalle C, Brinker TJ (2019)\nPrediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data.\nEur J Cancer. 2019 Sep;119:30-34.\nStepula E, K\u00f6nig M, Wang XP, Levermann J, Schimming T, Kasimir-Bauer S, Schilling B, Schl\u00fccker S (2019)\nLocalization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticles.\nJ Biophotonics. 2019;12:e201960034.\nStoevesandt J, Trautmann A (2019)\nBienen- und Wespengiftallergie in verschiedenen Lebensphasen.\nAkt Dermatol. 2019;45, 24-31.\nStoevesandt J, Trautmann A (2019)\nLessons from times of shortage: Interchangeability of venom preparations and dosing protocols.\nAllergy. 2019;74(7):1392-1395.\nSunderk\u00f6tter C, Aebischer A, Neufeld M, L\u00f6ser C, Kreuter A, Bialek R, Hamm H, Feldmeier H (2019)\nIncrease of scabies in Germany and development of resistant mites? Evidence and consequences.\nJ Dtsch Dermatol Ges. 2019;17(1):15-24.\nThiem A, Hesbacher S, Kneitz H, di Primio T, Heppt MV, Hermanns HM, Goebeler M, Meierjohann S, Houben R, Schrama D (2019)\nIFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.\nJ Exp Clin Cancer Res. 2019;38(1):397.\nTappenbeck N, Schr\u00f6der HM, Niebergall-Roth E, Hassinger F, Dehio U, Dieter K, Kraft K, Kerstan A, Esterlechner J, Frank NY, Scharffetter-Kochanek K, Murphy GF, Orgill DP, Beck J, Frank MH, Ganss C, Kluth MA (2019)\nIn vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials.\nCytotherapy. 2019;21(5):546-560.\nTrautmann A, Brockow K, Behle V, Stoevesandt J (2019)\nRadiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.\nJ Allergy Clin Immunol Pract. 2019;7(7):2218-2224.\nTrautmann A, Stoevesandt J. (2019)\nDifferential diagnosis of late-type reactions to injected local anaesthetics: Inflammation at the injection site is the only indicator of allergic hypersensitivity.\nContact Dermatitis. 2019;80, 118-124.\nWobser M, Goebeler M (2019)\nCutaneous lymphomas : Clinical presentation - diagnosis - treatment.\nHautarzt. 2019;70(10):815-830.\nPublikationen 2018\nAdam C, Gl\u00fcck L, Ebert R, Goebeler M, Jakob F, Schmidt M (2018)\nThe MEK5/ERK5 mitogen-activated protein kinase cascade is an effector pathway of bone-sustaining bisphosphonates that regulates osteogenic differentiation and mineralization.\nBone 111, 49-58.\nBaur J, Mathe K, Gesierich A, Weyandt G, Wiegering A, Germer CT, Pelz JOW (2018)\nImpact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients.\nJ Dermatolog Treat 29, 515-521.\nBecker JC, Stang A, Hausen AZ, Fischer N, DeCaprio JA, Tothill RW, Lyngaa R, Hansen UK, Ritter C, Nghiem P, Bichakjian CK, Ugurel S, Schrama D (2018)\nEpidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.\nCancer Immunol Immunother 67, 341-351.\nBenoit S, Scheurlen M, Goebeler M, Stoevesandt J (2018)\nStructured Diagnostic Approach and Risk Assessment in Mucous Membrane Pemphigoid with Oesophageal Involvement.\nActa Derm Venereol 98, 660-666.\nDippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Mei\u00df F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R (2018)\nS2k Guidelines -Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).\nJ Dtsch Dermatol Ges 16, 112-122.\nFan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC (2018)\nCirculating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma.\nClin Cancer Res 24, 5873-5882.\nFattouh K, Cunha N, Frings V, Hernandez-Aragues I, Stembridge N, Kuonen F (2018)\nWhat's new this month?\nEur J Dermatol 28, 134-135.\nFrings A, Frings V, Geerling G, Goebeler M, Schargus M. (2018) Progrediente Ulzeration der Periorbita. Ophthalmologe 115, 157-160.\nFrings V, Fattouh K, Hernandez Aragues I, Cunha N, Stembridge N, Kuonen F (2018)\nWhat\u2019s new this month?\nEur J Dermatol 28, 278-279.\nFrings VG, B\u00f6er-Auer A, Breuer K (2018)\nHistomorphology and Immunophenotype of Eczematous Skin Lesions Revisited-Skin Biopsies Are Not Reliable in Differentiating Allergic Contact Dermatitis, Irritant Contact Dermatitis, and Atopic Dermatitis.\nAm J Dermatopathol 40, 7-16.\nFrings VG, Goebeler M, Kneitz H (2018)\nDermpath & Clinic: In situ melanoma arising within a speckled lentiginous nevus.\nEur J Dermatol 28, 857-859.\nFrings VG, Goebeler M, Wobser M (2018)\nDermpath & Clinic: Juvenile xanthogranuloma.\nEur J Dermatol 28, 429-431.\nFrings VG, Sch\u00e4fer K, Strate A, Rosenwald A, Roth S, Kneitz H, Goebeler M, Geissinger E, Wobser M (2018, in press)\nParaproteinaemia in primary cutaneous marginal zone lymphoma.\nActa Derm Venereol 98, 956-962.\nGlossmann JP, Skoetz N, Starbatty B, Bischoff M, Leyvraz S, Westekemper H; AG SOP; Unter-AG Konjunktivales Melanom, Heindl LM (Collaborators: u. a. Gesierich A) (2018, in press)\nConjunctival melanoma: Standard operating procedures in diagnosis, treatment and follow-up care.\nOphthalmologe 115, 489-498.\nGlutsch V, Gesierich A, Goebeler M, Forster J, Schilling B (2018)\nNocardiosis in a patient with with anti-PD-1-associated colitis treated with imnfliximab.\nEur J Cancer 101, 284-286.\nGoebeler M (2018)\nBlasenbildende Autoimmunerkrankungen: zielgerichtete Diagnostik und multimodale Therapie.\nJ Dtsch Dermatol Ges 16, 1071-1072.\nGr\u00e4n F, Schwaneck EC, Rehn M, Strate A, Goebeler M, Benoit S (2018)\nKinderwunsch bei Lupus erythematodes \u2013 eine medizinische Herausforderung.\nJ Dtsch Dermatol Ges 16, 913-916.\nGrimm J, Hufnagel A, Wobser M, Borst A, Haferkamp S, Houben R, Meierjohann S (2018)\nBRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.\nOncogenesis 7, 71.\nHaug V, Behle V, Benoit S, Kneitz H, Schilling B, Goebeler M, Gesierich G (2018, in press)\nPembrolizumab-associated Mucous Membrane Pemphigoid in a Merkel cell carcinoma patient.\nBrit J Dermatol 179, 993-994.\nHaug V, Schilling B (2018)\nProgrammed death-1 blockade for multiple basal cell carcinomas: Clearing the field systemically?\nBrit J Dermatol 179, 566-567.\nHeratizadeh A , Werfel T , Schubert S , Geier J ; IVDK ( Collaborators: u. a. Trautmann A) (2018)\nContact sensitization in dental technicians with occupational contact dermatitis. Data of the Information Network of Departments of Dermatology (IVDK) 2001-2015.\nContact Dermatitis 78, 266-273.\nHerz C, Wirbelauer J, Hamm H (2018)\n4-j\u00e4hriger Junge mit Fieber, generalisierter R\u00f6tung und Blasen.\nHautarzt 69 (S2), 149-151.\nHoltsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman A, Levell NJ, Groves R, Williams HC, K\u00f6nig IR, Schmidt E; BLISTER Study Group (2018, in press)\nProspective study in bullous pemphigoid: Association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.\nBr J Dermatol 179, 918-924.\nJerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Ca\u00f1adas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A (2018)\nA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.\nCell 175, 984-997.\nK\u00e4hler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pf\u00f6hler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG) (2018)\nIpilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.\nCancer Immunol Immunother 67, 825-834.\nKervarrec T, Gaboriaud P, Berthon P, Zaragoza J, Schrama D, Houben R, Le Corre Y, Hainaut Wierzbicka E, Aubin F, Bens G, Domenech J, Guy\u00e9tant S, Touz\u00e9 A, Samimi M (2018)\nMerkel cell carcinomas infiltrated with CD33+ myeloid cells and CD8+ T cells are associated with improved outcome.\nJ Am Acad Dermatol. 78, 973-982.e8.\nKervarrec T, Samimi M, Gaboriaud P, Gheit T, Beby-Defaux A, Houben R, Schrama D, Fromont G, Tommasino M, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Maillard H, Furudo\u00ef A, Michenet P, Touz\u00e9 A, Guy\u00e9tant S (2018)\nDetection of the Merkel cell polyomavirus in the neuroendocrine component of combined Merkel cell carcinoma.\nVirchows Arch 472, 825-837.\nKirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L (2018)\nCan checkpoint inhibitor therapy improve response to chemotherapy?\nJ Cancer Res Clin Oncol 144, 183-185.\nKneitz H, Fetzer S, Goebeler M, Br\u00f6cker EB (2018)\nDifferenzialdiagnostische Bedeutung epithelialer und stromaler CD10-Expression in Tumoren trichogenen Ursprungs.\nJ Dtsch Dermatol Ges 16, 719-729.\nKugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT (2018)\nAge Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.\nClin Cancer Res 24, 5347-5356.\nMaurus K, Appenzeller S, Roth S, Kuper J, Rost S, Meierjohann S, Arampatzi P, Goebeler M, Rosenwald A, Geissinger E, Wobser M (2018)\nPanel Sequencing Reveals Recurrent Genetic FAS Alterations. In Primary Cutaneous Marginal Zone Lymphoma.\nJ Invest Dermatol 138, 1573-1581.\nMiao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM; Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM; Engelman JA, Getz G, Ja\u0308nne PA, Haddad RI, Choueiri TK, Barbie DA; Haq R, Awad MM; Schadendorf D, Hodi FS, Bellmunt J, Wong KK; Hammerman P, Van Allen EM(2018, in press)\nGenomic correlates of response to immune checkpoint blockade in microsatellite-stable solid\n[Tumors](/medien-kontakt/glossar/Tumors/?cHash=231a0cd23e385c9aa96a2e120c2fa07b).\nNature Genet 50, 1271-1281.\nMilsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M, Schadendorf D, Schilling B (2018)\nPatterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.\nEur J Cancer 99, 58-65.\nPieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, L\u00fcbcke S, Schr\u00f6rs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, W\u00f6lfel T, Schadendorf D, Schilling B, Paschen A, Zhao F (2018)\nEvolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment.\nOncoimmunology Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127.\nRecke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, Benoit S, El-Chennawy F, Eldarouti M, Eming R, Gl\u00e4ser R, G\u00fcnther C, Hadaschik E, Homey B, Lieb W, Peitsch WK, Pf\u00f6hler C, Robati RM, Saeedi M, S\u00e1rdy M, Sticherling M, Uzun S, Worm M, Zillikens D, Ibrahim S, Vidarsson G, Schmidt E; German AIBD Genetic Study Group (2018)\nThe p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts.\nFront Immunol Aug 2;9:1788. doi: 10.3389/fimmu.2018.01788.\nReichel A, Goebeler M, Weyandt G (2018)\nPerforierender Nasenwanddefekt: Verschluss mittels Kombinationslappenplastik.\nJ Dtsch Dermatol Ges 16, 1399-1401.\nSander D, Dietmeier W, Wobser M, Haferkamp S (2018)\nHyperkeratose der Brustwarze und des Warzenhofs: eine histologische Falle!\nJ Dtsch Dermatol Ges 16, 1368-1371\nSch\u00e4fer K, Cotofana S, Goebeler M, Weyandt G (2018, in press)\nLarge nasal defects with exposed cartilage: The folded transposition flap.\nDermatology 31, 1-16.\nSchmid C, Reichel A, Kerstan A, Gesierich A, Hamm H (2018)\nSlate-gray macules in the axillae.\nHautarzt 69, 177-179.\nSchmid FF, Groeber-Becker F, Schwab S, Thude S, Goebeler M, Walles H, Hansmann J (2018)\nA standardized method based on pigmented epidermal models evaluates sensitivity against UV-irridation.\nALTEX 35, 390-396.\nSchmidt M, Goebeler M (2018)\nInnate Immune System response in Metal Allergy: Toll-Like Receptors. In: Chen JK, Thyssen J (Hrg.): Metal Allergy. From Dermatitis to Implant and device Failure.\nSpringer-Verlag, Berlin-Heidelberg-New York S. 75-84.\nScholz S, Cosgarea I, S\u00fc\u00dfkind D, Murali R, Reis H, Leonardelli S, Schilling B, Schimming T, Hadaschik E, Franklin C, Paschen A, Sucker S, Steuhl KP, Schadendorf D, Westekemper H, Griewank K, M\u00f6ller I (2018)\nNF1 mutations in conjunctival melanoma.\nBrit J Cancer 118, 1243-1247.\nShukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, Neuberg D, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ (2018)\nCancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.\nCell 173, 624-633.e8.\nStoevesandt J, Hosp C, Kerstan A, Trautmann A (2018)\nSensitization to Hymenoptera Venom Marker Allergens: Prevalence, Predisposing Factors, and Clinical Implications.\nClin Exp Allergy 48, 1735-1743.\nStoevesandt J, Trautmann A (2018)\nFreshly squeezed: anaphylaxis caused by drone larvae juice.\nEur Ann Allergy Clin Immunol 50, 232-234.\nStolze I, Hamm H (2018)\nLichen nitidus and lichen striatus.\nHautarzt 69, 121-126.\nTeramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, T\u00fcting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C (2018)\nAcral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.\nBrit J Dermatol 178, 443-451.\nThiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A (2018, in press)\nEarly onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.\nMelanoma Res 28, 465-468.\nTrautmann A, Goebeler M, Stoevesandt J (2018)\nTwenty years' experience with anaphylaxis-like reactions to local anesthetics: genuine allergy is rare.\nJ Allergy Clin Immunol Pract 6, 2051-2058.e1.\nVogt T, Goebeler M(2018)\nLichenoid diseases.\nHautarzt 69, 98-99.\nPublikationen 2017\nAdam C, Wohlfarth J, Hau\u00dfmann M, Sennefelder H, Rodin A, Maler M, Martin SF, Goebeler M, Schmidt M (2017)\nAllergy-inducing chromium compounds trigger potent innate immune stimulation via ROS-dependent inflammasome activation.\nJ Invest Dermatol 137, 367-376.\nBaur J, Mathe K, Gesierich A, Weyandt G, Wiegering A, Germer CT, Gasser M, Pelz JOW (2017)\nMorbidity and oncologic outcome after saphenous vein-sparing inguinal lymphadenectomy in melanoma patients.\nWorld J Surg Oncol 15:99.\nBaur J, Mathe K, Gesierich A, Weyandt G, Wiegering A, Germer CT, Pelz JOW (2017)\nImpact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients.\nJ Dermatolog Treat 16:1-7. doi: 10.1080/09546634.2017.1398395.\nBecker JC, Lorenz E, Ugurel S, Eigentler TK, Kiecker F, Pf\u00f6hler C, Kellner I, Meier F, K\u00e4hler K, Mohr P, Berking C, Haas G, Helwig C, Oksen D, Schadendorf D, Mahnke L, Bharmal M (2017)\nEvaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.\nOncotarget 8(45):79731-79741 doi: 10.18632/oncotarget.19218.\nBehle V, von Braunm\u00fchl T, Sayehli C, Gesierich A, Goebeler M, Geissinger E, Wobser M (2017)\nS\u00e9zary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.\nActa Derm Venereol 97, 973-975.\nBorst A, Haferkamp S, Grimm J, R\u00f6sch M, Zhu G, Guo S, Li C, Gao T, Meierjohann S, Schrama D, Houben R (2017 in press)\nBIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.\nCancer Letters Letters 404, 70-78.\nCunha N, Fattouh K, Frings V, Hernandez-Aragues I, Stembridge N, Kuonen F (2017)\nWhat\u2019s new this month?\nEur J Dermatol 27, 678-679.\nCunha N, Stembridge N, Frings V, Fattouh K, Hernandez-Aragues I, Kuonen F (2017)\nEditorial: What's new this month?\nEur J Dermatol 27, 446-447.\nDippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Mei\u00df F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R (2017)\nS2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86).\nJ Dtsch Dermatol Ges 15, 1266-1273.\nDogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, Houben R, Haferkamp S, P\u00fcschel AW, Krahn MP (2017)\nMembrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.\nNat Commun 8:15747 doi:10.1038/ncomms15747.\nFranklin C, Rooms I, Fiedler M, Reis H, Milsch L, Herz S, Livingstone E, Zimmer L, Schmid KW, Dittmer U, Schadendorf D, Schilling B (2017)\nCytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.\nEur J Cancer 86, 248-256.\nFrings A, Frings V, Geerling G, Goebeler M, Schargus M (2017, in press)\nProgrediente Ulzeration der Periorbita.\nOphthalmologe, doi:10.1007/s00347-017-0512-0.\nFrings V, Fattouh K, Hernandez-Aragues I, Cunha N, Stembridge N, Kuonen F (2017)\nEditorial: What's new this month?\nEur J Dermatol 27, 214-215.\nFrings VG, B\u00f6er-Auer A, Breuer K (2017, in press)\nHistomorphology and Immunophenotype of Eczematous Skin Lesions Revisited-Skin Biopsies Are Not Reliable in Differentiating Allergic Contact Dermatitis, Irritant Contact Dermatitis, and Atopic Dermatitis.\nAm J Dermatopathol.\nFrings VG, Goebeler M, Kneitz H (2017)\nDermpath & Clinic: Giant trichoblastoma of the leg.\nEur J Dermatol 27, 447-448.\nFrings VG, Hamm H (2017)\nDermatologische Manifestationen der tuber\u00f6sen Sklerose (TSC) (Leserbrief zu Ebrahimi-Fakhari D et al., J Dtsch Dermatol Ges 15, 695-701).\nJ Dtsch Dermatol Ges 15, 1155-1156.\nFrings VG, Roth S, Riedmiller AL, Sch\u00e4fer K, Goebeler M, Rosenwald A, Geissinger E, Wobser M (2017)\nPrimary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20.\nActa Derm Venereol 97, 534-536.\nFrings VG, Trautmann A, Goebeler M, Wobser M. (2017) Dermpath & Clinic: Multiple reactive eccrine syringofibroadenomas. Eur J Dermatol 27, 102-104.\nGassenmaier M, Eigentler TK, Keim U, Goebeler M, Eckhard Fiedler E, Gerold Schuler G, Ulrike Leiter U, Weide B, Grischke EM, Martus P, Garbe C (2017)\nSerial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.\nJ Invest Dermatol 137, 2570-2577.\nGiner T, Benoit S, Kneitz H, Goebeler M (2017, in press)\nSarkoidose \u2013 der dermatologische Blick auf eine seltene Multisystemerkrankung.\nHautarzt 68, 526-535.\nGriewank KG, M\u00fcller H, Jackett LA, Emberger M, M\u00f6ller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, R\u00fctten A, Murali R, Scolyer RA, Schadendorf D (2017, in press)\nSF3B1 and BAP1 mutations in blue nevus-like melanoma.\nMod Pathol 30, 928-939.\nGriewank KG, Paschen A (2017)\nAcquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.\nNat Commun 8:15440 doi:10.1038/ncomms15440.\nGutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pf\u00f6hler C, Gesierich A, Livingstone E, Satzger I, K\u00e4hler KC; German Dermatooncology Group (DeCOG) (2017)\nProgrammed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.\nEur J Cancer 75, 24-32.\nHamm H (2017)\nKr\u00e4tzealarm im Altenheim.\nMMW Fortschr Med 159, 22.\nHaug V, Benoit S, Wohlleben M, Hamm H (2017, in press)\nAnnular pustular psoriasis in a 14-month-old girl: a therapeutic challenge.\nJ Dermatolog Treat 28, 520-522.\nHaymerle G, Janik S, Fochtmann A, Pammer J, Schachner H, Nemec L, Mildner M, Houben R, Grasl MC, Erovic BM (2017)\nExpression of Merkel cell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome.\nPLoS One Aug 1;12(8):e0180426. doi: 10.1371/journal.pone.0180426.\nHelbig D, Quaas A, Mauch C, Merkelbach-Bruse S, B\u00fcttner R, Emberger M, Wobser M, R\u00fcsseler V, P\u00fctz K, Binot E, Rehker J, Budczies J, Ihle MA (2017)\nCopy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.\nOncotarget 8, 109457-109467.\nHeppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C (2017)\nPrognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.\nBMC Cancer Aug 10;17(1):536. doi: 10.1186/s12885-017-3529-5.\nHeppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, K\u00e4hler KC, Gesierich A, Meissner M, von Bubnoff D, G\u00f6ppner D, Schlaak M, Pf\u00f6hler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C (2017)\nPrognostic factors and treatment outcomes in 444 patients with mucosal melanoma.\nEur J Cancer 81, 36-44.\nHernandez-Aragues I, Cunha N, Fattouh K, Frings V, Stembridge N, Kuonen F (2017)\nWhat's new this month?\nEur J Dermatol 27, 335-336.\nHosp C, Hamm H. (2017, in press) Safety of available and emerging drug therapies for hyperhidrosis. Exp Opin Drug Safety 16, 1039-1049.\nImprota G, Ritter C, Pettinato A, Vasta V, Schrama D, Fraggetta F, Becker JC (2017, in press)\nMGMT promoter methylation status in Merkel cell carcinoma: in vitro versus in vivo.\nJ Cancer Res Clin Oncol 143, 1489-1497.\nKhalil AA, Ilina O, Gritsenko PG, Bult P, Span PN, Friedl P (2017)\nCollective invasion in ductal and lobular breast cancer associates with distant metastasis.\nClin Exp Metastasis 34, 421-429.\nM.B. Faries, J.F. Thompson, A.J. Cochran, R.H. Andtbacka, N. Mozzillo, J.S. Zager, T. Jahkola, T.L. Bowles, A. Testori, P.D. Beitsch, H.J. Hoekstra, M. Moncrieff, C. Ingvar, M.W.J.M. Wouters, M.S. Sabel, E.A. Levine, D. Agnese, M. Henderson, R. Dummer, C.R. Rossi, R.I. Neves, S.D. Trocha, F. Wright, D.R. Byrd, M. Matter, E. Hsueh, A. MacKenzieRoss, D.B. Johnson, P. Terheyden, A.C. Berger, T.L. Huston, J.D. Wayne, B.M. Smithers, H.B. Neuman, S. Schneebaum, J.E. Gershenwald, C.E. Ariyan, D.C. Desai, L. Jacobs, K.M. McMasters, A. Gesierich, P. Hersey, S.D. Bines, J.M. Kane, R.J. Barth, G. McKinnon, J.M. Farma, E. Schultz, S. Vidal\u2010Sicart, R.A. Hoefer, J.M. Lewis, R. Scheri, M.C. Kelley, O.E. Nieweg, R.D. Noyes, D.S.B. Hoon, H. J. Wang, D.A. Elashoff, and R.M. Elashoff (2017)\nCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.\nNew Engl J Med 376, 2211-2222.\nMergler R, Kerstan A, Schmidt E, Goebeler M, Benoit S (2017)\nAtypical clinical and serological manifestation of pemphigus vegetans: a case report and review of the literature.\nCase Rep Dermatol 9, 121\u2013130.\nMindorf S, Dettmann IM, Kr\u00fcger S, Fuhrmann T, Rentzsch K, Karl I, Probst C, Komorowski L, Fechner K, van Beek N, Lemcke S, S\u00e1rdy M, Bangert C, Benoit S, Hashimoto T, Zillikens D, Pas HH, Jonkman MF, St\u00f6cker W, Schmidt E, International Autoimmune Bullous Diseases Study Group (2017)\nRoutine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical Pemphigus.\nExp Dermatol 26, 1267-1270.\nM\u00fcller-Richter UDA, Gesierich A, K\u00fcbler AC, Hartmann S, Brands RC (2017)\nMerkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.\nAnn Surg Oncol 24, 3430-3427.\nOfner R, Ritter C, Heidenreich B, Kumar R, Ugurel S, Schrama D, Becker JC (2017)\nDistribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.\nJ Cancer Res Clin Oncol 143, 613-617.\nOfner R, Ritter C, Ugurel S, Cerroni L, Stiller M, Bogenrieder T, Solca F, Schrama D, Becker JC (2017)\nNon-reproducible sequence artifacts in FFPE tissue: an experience Report.\nJ Cancer Res Clin Oncol 143, 1199-1207.\nOji V, Preil ML, Kleinow B, Wehr G, Fischer J, Hennies HC, Hausser I, Breitkreutz D, Aufenvenne K, Stieler K, Tantcheva-Po\u00f3r I, Weidinger S, Emmert S, Hamm H, Perusquia-Ortiz AM, Zaraeva I, Diem A, Giehl K, F\u00f6lster-Holst R, Kiekbusch K, H\u00f6ger P, Ott H, Traupe H (2017)\nS1 guidelines for the diagnosis and treatment of ichthyoses \u2013 update.\nJ Dtsch Dermatol Ges 15, 1053-1065.\nPapapanagiotou M, Griewank KG, Hillen U, Schimming TT, Moeller LC, F\u00fchrer D, Zimmer L, Roesch A, Sucker A, Schadendorf D, Livingstone E, Schilling B (2017)\nTrametinib-Induced Remission of an MEK1-Mutated Langerhans Cell Histiocytosis.\nJCO Precision Oncology doi: 10.1200/PO.16.00070.\nPrince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dr\u00e9no B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M2 and the ALCANZA study group (Collaborators: Trotman J, Joske D, Prince HM, Taylor K, Lewis ID, Jonak C, Trautinger F, Bechter O, Wolter P, Bron D, de Lima VCC, Sanches JA Junior, Klasa R, Bagot M, Beylot-Barry M, Dalle S, D'Incan M, Dreno B, Grange F, Nicolay J, Stadler R, Weichenthal M, Wobser M, Assaf C, Loquai C, Quaglino P, Spina M, Zinzani PL, Bosi A, Fattori PP, Grzanka A, Walewski J, Lopez-Hernandez A, Ortiz-Romero PL, Roca JJR, Canales SN, Dummer R, Illidge T, Johnson R, Whittaker S, Morris S, McKay P, Scarisbrick J, Duvic M, Feldman T, Akilov O, Geskin L, Horwitz S, Kim YH, Pro B, Kuzel T, Lerner A, Eradat H, Sokol L, Fisher DC, Hughey S) (2017)\nBrentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.\nLancet 390, 555-566.\nReichel A, Benoit S, Giner T, Schmidt E, Goebeler M, Stoevesandt J (2017)\nAnti-Desmoglein 1 IgG/IgA-Pemphigus in Verbindung mit einem Thymom.\nJ Dtsch Dermatol Ges 15, 1147-1149.\nReichel A, Hamm H, Wiegering V, Wiewrodt B, Neubauer H, Ernestus K, Winkler B (2017)\nKaposiformes H\u00e4mangioendotheliom mit Kasabach-Merritt-Syndrom: erfolgreiche Therapie mit Sirolimus.\nJ Dtsch Dermatol Ges 15, 329-331.\nRitter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC (2017)\nEpigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.\nSci Rep 7(1):2290. doi:10.1038/s41598-017-02608-0.\nSadik CD, Bischof J, van Beek N, Dieterich A, Benoit S, S\u00e1rdy M, Worm M, Meller S, Gl\u00e4ser R, Zillikens D, Homey B, Setterfield J, Minassian D, Schmidt E, Dart J; MMP study group 2009 - 2014; Autoimmune Bullous Diseases Study Group, Ibrahim SM (2017)\nGenome-wide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid.\nExp Dermatol 26, 2014-2020.\nSadik CD, Pas HH, Bohlmann MK, Mousavi S, Benoit S, S\u00e1rdy M, Terra JB, Lima AL, Hammers CM, van Beek N, Bangert C, Zillikens D, Schmidt E (2017)\nValue of BIOCHIP Technology in the Serological Diagnosis of Pemphigoid Gestationis.\nActa Derm Venereol 97, 128-130.\nSch\u00e4fer K, Bauer B, Donhauser J, Kerstan A, Hamm H (2017)\nBecker Naevus Syndrome of the Lower Body: One Case and Review of the Literature.\nActa Derm Venereol 97, 499-504.\nSchmidt E, Benoit S, Kampik D, Hille K, Geerling G (2017)\nTibial bone keratoprosthesis: reversing blindness in mucous membrane pemphigoid.\nJ Dtsch Dermatol Ges 15, 1024-1026.\nSchmidt T, Hoch M, Lotfi Jad SS, Solimani F, Di Zenzo G, Marzano AV, Goebeler M, Cozzani E, Kern JS, Sitaru C, Lako\u0161 Juki\u0107 I, S\u00e1rdy M, Uzun S, Jedlickova H, Gl\u00e4ser R, Kaneda M, Eming R, G\u00f6pel G, Ishii N, Greene B, Hashimoto T, Hertl M (2017, in press)\nSerological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita - a multicenter analysis.\nBrit J Dermatol.\nSchmidt T, Hoch M, Lotfi Jad SS, Solimani F, Di Zenzo G, Marzano AV, Goebeler M, Cozzani E, Kern JS, Sitaru C, Lako\u0161 Juki\u0107 I, S\u00e1rdy M, Uzun S, Jedlickova H, Gl\u00e4ser R, Kaneda M, Eming R, G\u00f6pel G, Ishii N, Greene B, Hashimoto T, Hertl M (2017)\nSerological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita - a multicenter analysis.\nBrit J Dermatol 177, 1683-1692.\nScholz SL, M\u00f6ller I, Reis H, S\u00fc\u00dfkind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG (2017)\nFrequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.\nInvest Ophthalmol Vis Sci 58, 3464-3470.\nSchrama D, Ritter C, Becker JC (2017)\nT cell receptor repertoire usage in cancer as a surrogate marker for immune Responses.\nSemin Immunopathol 39, 255-268.\nSekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators (2017)\nLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.\nBMC Cancer 17, 332. doi:10.1186/s12885-017-3286-5.\nStembridge N, Cunha N, Frings V, Fattouh K, Hernandez-Aragues I, Kuonen F (2017)\nEditorial: What's new this month?\nEur J Dermatol 27, 565-566.\nSticherling M, Franke A, Aberer E, Gl\u00e4ser R, Hertl M, Pfeiffer C, Rzany B, Schneider S, Shimanovich I, Werfel T, Wilczek A, Zillikens D, Schmidt A (2017)\nAn open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.\nBrit J Dermatol 177, 1299-1305.\nStoevesandt J, Hosp C, Kerstan A, Trautmann A (2017)\nSafety of 100 \u00b5g venom immunotherapy rush protocols in children compared to adults.\nAllergy Asthma Clin Immunol 13:32 doi: 10.1186/s13223-017-0204-y.\nSucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A (2017)\nAcquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.\nNat Commun 8:15440 doi:10.1038/ncomms15440.\nTeramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, T\u00fcting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C (2017, in press)\nAcral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.\nBrit J Dermatol.\nThiem A, Kneitz H, Schummer P, Herz S, Schrama D, Houben R, Goebeler M, Schilling B, Gesierich A (2017)\nCoincident metastatic melanoma and Merkel cell carcinoma with complete remission upon treatment with pembrolizumab.\nActa Derm Venereol 97, 1252-1254.\nToksoy A, Sennefelder H, Adam C, Hofmann S, Trautmann A, Goebeler M, Schmidt M (2017)\nPotent NLRP3 Inflammasome Activation by the HIV Reverse Transcriptase Inhibitor Abacavir.\nJ Biol Chem 292, 2805-2814.\nToksoy A, Strifler S, Benoit S, Grigoleit GU, Knop S, Mielke S, Buder-Bakhaya K, Roth S, Goebeler M, Rosenwald A, Geissinger E, Wobser M (2017)\nFacial Swelling and Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr Virus-associated T-cell Lymphoproliferation with Subsequent Development of Lymphoma.\nActa Derm Venereol 97, 379-380.\nTrautmann A, Benoit S, Goebeler M, Stoevesandt J (2017, in press)\n\"Treating Through\" Decision and Follow-up in Antibiotic Therapy-Associated Exanthemas.\nJ Allergy Clin Immunol Pract 5, 1650-1656.\nTrautmann A, Stoevesandt J (2017)\nReply.\nJ Allergy Clin Immunol Pract 5, 535-536.\nUgurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderk\u00f6tter C, Stein A, Fluck M, Kaatz M, Trefzer U, K\u00e4hler K, Stadler R, Berking C, H\u00f6ller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC (2017)\nChemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.\nOncotarget 8, 76029-76043 doi: 10.18632/oncotarget. 18635.\nWalter E, Vielmuth F, Rotkopf L, S\u00e1rdy M, Horv\u00e1th ON, Goebeler M, Schmidt E, Eming R, Hertl M, Spindler V, Waschke J (2017)\nDifferent signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus.\nSci Rep 7(1):3579. doi:10.1038/s41598-017-03697-7.\nWilliams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group (Collaborators: u. a. Br\u00f6cker EB) (2017)\nDoxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled Trial.\nLancet 389, 1630-1638.\nWobser M, Maurus K, Roth S, Appenzeller S, Weyandt G, Goebeler M, Rosenwald A, Geissinger E (2017)\nMYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype.\nBr J Dermatol 177, 564-566.\nZouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak L, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R on behalf oft he EHSF Investigator Group (2017)\nDevelopment and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity.\nBr J Dermatol 177, 1401-1409.\nPublikationen 2016\nAlmanzar G, Klein M, Schmalzing M, Hilligardt D, El Hajj N, Kneitz H, Wild V, Rosenwald A, Benoit S, Hamm H, Tony HP, Haaf T, Goebeler M, Prelog M (2016)\nDisease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and RORC/FoxP3 Methylation in Systemic Sclerosis.\nInt Arch Allergy Immunol 171, 141-154.\nAlrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E (2016)\nNFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.\nNat Commun 7, 11724.\nBasmanav FB, Cau L, Tafazzoli A, M\u00e9chin MC, Wolf S, Romano MT, Valentin F, Wiegmann H, Huchenq A, Kandil R, Garcia Bartels N, Kilic A, George S, Ralser DJ, Bergner S, Ferguson DJ, Oprisoreanu AM, Wehner M, Thiele H, Altm\u00fcller J, N\u00fcrnberg P, Swan D, Houniet D, B\u00fcchner A, Weibel L, Wagner N, Grimalt R, Bygum A, Serre G, Blume-Peytavi U, Sprecher E, Schoch S, Oji V, Hamm H, Farrant P, Simon M, Betz RC (2016)\nMutations in Three Genes Encoding Proteins Involved in Hair Shaft Formation Cause Uncombable Hair Syndrome.\nAm J Hum Genet 99, 1292-1304.\nBehle V, Goebeler M, Gesierich A (2016)\nSeriously saRComa: Neurofibrosarcoma.\nEur J Dermatol 26, 517-518.\nBehle V, Wobser M, Goebeler M, Stoevesandt J (2016)\nExtensive molluscum contagiosum virus infection in a young adult receiving fingolimod.\nMult Scler 22, 969-71.\nBluemel C, Safak G, Cramer A, W\u00f6ckel A, Gesierich A, Hartmann E, Schmid JS, Kaiser F, Buck AK, Herrmann K (2016)\nFusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes.\nEur J Nucl Med Mol Imaging 43, 2304-2312.\nBr\u00f6cker E, Gollnick H, Goerdt S, Malte-Baron J (2016)\nObituary: Professor Martin Leverkus: 1965-2016.\nBr J Dermatol 174, 1424-1245.\nBr\u00f6cker E, Gollnick H, Goerdt S, Baron JM (2016)\nMartin Leverkus \u2013 Nachruf.\nJ Dtsch Dermatol Ges 14, 459-61.\nDieckmann R, Boone I, Brockmann SO, Hammerl JA, Kolb-M\u00e4urer A, Goebeler M, Luch A, Dahouk SA (2016)\nRisiken f\u00fcr bakterielle Infektionen nach T\u00e4towierungen. Ein systematisches Literaturreview.\nDtsch Arztebl Int 113, 665-71.\nEllerbroek V, Hamm H (2016)\nPityriasis Lichenoides et Varioliformis Acuta: Remission with Hypopigmentation.\nJ Pediatr 176, 211-211.\nHamm H (2016)\nKinderdermatologie: ein Kleinod unseres Fachgebiets.\nJ Dtsch Dermatol Ges 14, 345-6.\nHamm H (2016)\nSeverely impaired quality of life. \"My sweating is intolerable.\".\nMMW Fortschr Med 158, 46-50.\nHesbacher S, Pfitzer L, Wiedorfer K, Angermeyer S, Borst A, Haferkamp S, Scholz CJ, Wobser M, Schrama D, Houben R (2016)\nRB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells.\nOncotarget 7, 32956-32968.\nHofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Thomas J, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016)\nCutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.\nEur J Cancer 60, 190-209.\nHosp C, Naumann MK, Hamm H (2016)\nBotulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.\nSemin Neurol 36, 20-8.\nKarademir F, Rose C, Goebeler M, Kneitz H, Hamm H, Wobser M (2016)\nMultiple eruptive Angiofibrome bei einem 14-j\u00e4hrigen M\u00e4dchen.\nJ Dtsch Dermatol Ges 14, 746-748.\nKlein M, Schmalzing M, Almanzar G, Benoit S, Hamm H, Tony HP, Goebeler M, Prelog M (2016)\nContribution of CD8+ T cells to inflammatory cytokine production in systemic sclerosis (SSc).\nAutoimmunity 25, 1-15.\nLange J, Weil F, Riegler C, Groeber F, Rebhan S, Kurdyn S, Alb M, Kneitz H, Gelbrich G, Walles H, Mielke S (2016)\nInteractions of donor sources and media influence the histomorphological quality of full-thickness skin models.\nBiotechnol J 11, 1352-1361.\nLengfeld J, Buder-Bakhaya K, Goebeler M, Wobser M (2016)\nBisphosphonate-Mediated Oral Ulcers: A Rare Differential Diagnosis of Erosive Oral Lesions.\nDermatology 232, 117-121.\nLima AL, Karl I, Giner T, Poppe H, Schmidt M, Presser D, Goebeler M, Bauer B (2016)\nKeratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.\nBr J Dermatol 174, 514-521.\nMoinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, Mueller-Ladner U, Frerix M, Kreuter A, Tigges C, Lahner N, Susok L, Guenther C, Zeidler G, Pfeiffer C, Worm M, Karrer S, Aberer E, Bretterklieber A, Genth E, Simon JC, Distler JH, Hein R, Schneider M, Seitz CS, Herink C, Steinbrink K, S\u00e1rdy M, Varga R, Mensing H, Mensing C, Lehmann P, Neeck G, Fiehn C, Weber M, Goebeler M, Burkhardt H, Buslau M, Ahmadi-Simab K, Himsel A, Juche A, Koetter I, Kuhn A, Sticherling M, Hellmich M, Kuhr K, Krieg T, Ehrchen J, Sunderkoetter C, Hunzelmann N, German Network for Systemic Scleroderma (2016)\nVasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.\nJ Rheumatol 43, 66-74.\nM\u00fcller-Richter UD, Weyandt GH, Woeckel A, K\u00fcbler AC (2016)\nVermilion Reconstruction with Genital Mucosa.\nPlast Reconstr Surg Glob Open 4(5):e701.\nNicolay JP, Wobser M (2016)\nCutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.\nJ Dtsch Dermatol Ges 14, 1207-1224.\nOchsendorf F, Bandholz T, Emmert S, Hartmann K, Hartmann M, Hornung T, J\u00fcnger M, Kollewe T, L\u00f6ser C, Moll I, Psotta-Schachtner C, Spornraft-Ragaller P, St\u00e4nder S, von Stebut-Borschitz E, Hamm H (2016)\n111 Top-Lernziele Dermatologie: Lernzielkatalog f\u00fcr Haut- und Geschlechtskrankheiten der Deutschen Dermatologischen Gesellschaft.\nJ Dtsch Dermatol Ges 14, 637-43.\nRitter C, Fan K, Paulson KG, Nghiem P, Schrama D, Becker JC (2016)\nReversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.\nSci Rep 6, 21678.\nSchmidt M, Goebeler M, Martin SF (2016)\nMethods to Investigate the Role of Toll-Like Receptors in Allergic Contact Dermatitis.\nMethods Mol Biol 1390, 319-40.\nSchrama D, Hesbacher S, Angermeyer S, Schlosser A, Haferkamp S, Aue A, Adam C, Weber A, Schmidt M, Houben R (2016)\nSerine 220 phosphorylation of the Merkel cell polyomavirus Large T antigen crucially supports growth of Merkel cell carcinoma cells.\nInt J Cancer 138, 1153-62.\nStolze I, Trautmann A, Goebeler M, Stoevesandt J. (2016) Dangerous Leg Cramps: Severe Pustular Exanthema Caused by an Over-the-Counter Drug. Acta Derm Venereol 96, 703-704.\nSunderk\u00f6tter C, Feldmeier H, F\u00f6lster-Holst R, Geisel B, Klinke-Rehbein S, Nast A, Philipp S, Sachs B, Stingl J, Stoevesandt J, Hamm H (2016)\nS1-Leitlinie zur Diagnostik und Therapie der Skabies - Kurzfassung.\nJ Dtsch Dermatol Ges 14, 1160-1171.\nThiem A, K\u00fctt S, Hamm H (2016)\n'Television alopecia': a rare cause of pressure alopecia.\nJ Eur Acad Dermatol Venereol 30, 504-505.\nThiem A, Mergler R, Kneitz H, Weyandt G, Goebeler M, Gesierich A (2016)\nAcne inversa-like skin lesions as a potential adverse event during vemurafenib therapy.\nJ Dtsch Dermatol Ges 14, 427-8.\nThomas AC, Zeng Z, Rivi\u00e8re JB, O'Shaughnessy R, Al-Olabi L, St-Onge J, Atherton DJ, Aubert H, Bagazgoitia L, Barbarot S, Bourrat E, Chiaverini C, Chong WK, Duffourd Y, Glover M, Groesser L, Hadj-Rabia S, Hamm H, Happle R, Mushtaq I, Lacour JP, Waelchli R, Wobser M, Vabres P, Patton EE, Kinsler VA (2016)\nMosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.\nJ Invest Dermatol 136, 770-8.\nTrautmann A, Anders D, Stoevesandt J (2016)\nH1-Antihistamine Premedication in NSAID-Associated Urticaria.\nJ Allergy Clin Immunol Pract 4, 1205-1212.\nTrautmann A, Seidl C, Stoevesandt J, Seitz CS (2016)\nGeneral anaesthesia-induced anaphylaxis: impact of allergy testing on subsequent anaesthesia.\nClin Exp Allergy 46, 125-32.\nWiedemann K, Schmid C, Hamm H, Wirbelauer J (2016)\nStaphylococcal Scalded Skin Syndrome in a Very Low Birth Weight Premature Infant.\nZ Geburtshilfe Neonatol 220, 25-8.\nWillmes C, Kumar R, Becker JC, Fried I, Rachakonda PS, Poppe LM, Hesbacher S, Schadendorf D, Sucker A, Schrama D, Ugurel S (2016)\nSERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.\nOncotarget 7, 10117-32.\nWobser M, Reinartz T, Roth S, Goebeler M, Rosenwald A, Geissinger E (2016)\nCutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.\nOncol Ther 4, 199-210.\nZhu G, Yi X, Haferkamp S, Hesbacher S, Li C, Goebeler M, Gao T, Houben R, Schrama D (2016)\nCombination with \u03b3-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.\nCancer Lett 376, 43-52.\nZiegler W, Lempert S, Goebeler M, Kolb-M\u00e4urer A (2016)\nTinea capitis: Erregerspektrum und Epidemiologie im zeitlichen Wandel.\nJ Dtsch Dermatol Ges 14, 818-26.\nZimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentlicher T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016)\nNeurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.\nEur J Cancer 60, 210-25.\nPublikationen 2015\nBauer B, Trautmann A (2015)\nSwollen Ears and Nose Bleeding Accompanied by Skin Papules.\nPediatr Dermatol 32, 863-4.\nBauer B, Goebeler M, Weissbrich B, Kerstan A (2015)\nKerinokeratosis Papulosa of Childhood.\nDermatology 231, 1-4.\nBehle V, Goebeler M (2015)\nResidents'corner April 2015. Seriously saRComa!: Dermatofibrosarcoma protuberans.\nEur J Dermatol 25, 214.\nBehle V, Kneitz H, Goebeler M (2015)\nResidents' corner October 2015. Seriously saRComa!: Atypical fibroxanthoma.\nEur J Dermatol 25, 520-1.\nBenoit S, Goebeler M (2015)\nMepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?\nActa Derm Venereol 95, 596-9.\nBenoit S, Hamm H (2015)\nDifferenzialdiagnose erosiver und ulzer\u00f6ser Mundschleimhauterkrankungen im Kindesalter.\nHautarzt 66, 258-66.\nBrenner I, Roth S, Flossbach L, Wobser M, Rosenwald A, Geissinger E (2015)\nLack of MYD88 L265P Mutation in Primary Cutaneous Marginal Zone Lymphoma.\nBrit J Dermatol 173, 1527-1528.\nBrockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, Fuchs T, Jakob T, Lange L, Pf\u00fctzner W, Mockenhaupt M, Ott H, Pfaar O, Ring J, Sachs B, Sitter H, Trautmann A, Treudler R, Wedi B, Worm M, Wurpts G, Zuberbier T, Merk HF (2015)\nGuideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (\u00d6GAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM).\nAllergo J Int 24, 94-105.\nChalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group (Kollaboratoren: u. a. Benoit S) (2015)\nA randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.\nBr J Dermatol 173, 227-34.\nErfle H, Pashayeva K, Harder N, Zhang L, Rohr K, Schadendorf D, Ugurel S, Keese M (2015)\nTargeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes.\nBiotechnol J 10, 1467-77.\nFlorence ME, Massuda JY, Soares TC, Stelini RF, Poppe LM, Br\u00f6cker EB, Metze K, Cintra ML, de Souza EM (2015)\np53 immunoexpression in stepwise progression of cutaneous squamous cell carcinoma and correlation with angiogenesis and cellular proliferation.\nPathol Res Pract 211, 782-8.\nGriffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators (Kollaboratoren: u. a. Benoit S) (2015)\nComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.\nLancet 386, 541-51.\nHamm H, H\u00f6ger PH (2015)\nNachwuchsprobleme.\nHautarzt 66, 234-35.\nHill R, Kalathur RK, Cola\u00e7o L, Brand\u00e3o R, Ugurel S, Futschik M, Link W (2015)\nTRIB2 as a biomarker for diagnosis and progression of melanoma.\nCarcinogenesis 36, 469-77.\nHirose M, Schilf P, Benoit S, Eming R, Gl\u00e4ser R, Homey B, Kunz M, Nebel A, Peitsch WK, Pf\u00f6hler C, S\u00e1rdy M, Schreiber S, Zillikens D, Schmidt E, Ibrahim SM; German AIBD Genetic Study Group (2015)\nPolymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population.\nExp Dermatol 24, 715-7.\nH\u00f6ger PH, Hamm H (2015)\nPsoriasis vulgaris bei Kindern und Jugendlichen.\nHautarzt 66, 267-76.\nHouben R, Angermeyer S, Haferkamp S, Aue A, Goebeler M, Schrama D, Hesbacher S (2015)\nCharacterization of functional domains in the Merkel cell polyoma virus Large T antigen.\nInt J Cancer 136, E290-300.\nHuth S, Heise R, Vetter-Kauczok CS, Skazik C, Marquardt Y, Czaja K, Kn\u00fcchel R, Merk HF, Dahl E, Baron JM (2015)\nInter-\u03b1-trypsin inhibitor heavy chain 5 (ITIH5) is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models.\nExp Dermatol 24, 663-8.\nKneitz H, Mentzel T, Wobser M, Goebeler M (2015)\nKutanes PECom des rechten Unterschenkels.\nJDDG 13, 815-7.\nKneitz H, Motschenbacher S, Wobser M, Goebeler M (2015)\nPhotoletter to the editor: Giant cutaneous horn associated with squamous cell carcinoma.\nJ Dermatol Case Rep 9, 27-8.\nKneitz H, Wobser M, Stoevesandt J, Goebeler M (2015)\nTherapieresistente purulente Papeln und Knoten gluteal und im Bereich beider Oberschenkel.\nHautarzt 66, 636-8.\nKolb-M\u00e4urer A, Goebeler M, M\u00e4urer M (2015)\nCutaneous Adverse Events Associated with Interferon-\u03b2 Treatment of Multiple Sclerosis.\nInt J Mol Sci 16, 14951-60.\nKomaravolu RK, Adam C, Moonen JR, Harmsen MC, Goebeler M, Schmidt M (2015)\nErk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1.\nCardiovasc Res 105, 86-95.\nLeikam C, Hufnagel AL, Otto C, Murphy DJ, M\u00fchling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp S, Br\u00f6cker EB, Schartl M, Meierjohann S (2015)\nIn vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells.\nCell Death Dis 6:e1711.\nLengfeld J, Kneitz H, Goebeler M, Kolb-M\u00e4urer A (2015)\nPanniculitis due to pancreatic disease.\nJDDG 13, 807-9.\nMoonen JR, Lee ES, Schmidt M, Maleszewska M, Koerts JA, Brouwer LA, van Kooten TG, van Luyn MJ, Zeebregts CJ, Krenning G, Harmsen MC (2015)\nEndothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress.\nCardiovasc Res 108, 377-86.\nM\u00f6ssner R, Zimmer L, Berking C, Hoeller C, Loquai C, Richtig E, K\u00e4hler KC, Hassel JC, Gutzmer R, Ugurel S (2015)\nErythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.\nJ Eur Acad Dermatol Venereol 29, 1797-806.\nOdongo L, Mulyowa G, Goebeler M, Trautmann A (2015)\nBet v 1- and Bet v 2-Associated Plant Food Sensitization in Uganda and Germany: Differences and Similarities.\nInt Arch Allergy Immunol 167, 264-269.\nPoppe H, Kerstan A, B\u00f6ckers M, Goebeler M, Geissinger E, Rosenwald A, Hamm H (2015)\nChildhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype.\nJ Cutan Pathol 42, 258-64.\nRecke A, Vidarsson G, Ludwig RJ, Freitag M, M\u00f6ller S, Vonthein R, Schellenberger J, Haase O, G\u00f6rg S, Nebel A, Flachsbart F, Schreiber S, Lieb W, Gl\u00e4ser R, Benoit S, S\u00e1rdy M, Eming R, Hertl M, Zillikens D, K\u00f6nig IR, Schmidt E, Ibrahim S; German AIBD Genetic Study Group. Collaborators (18) Benoit S, D\u00e4schlein G, Eming R, Gl\u00e4ser R, Goebeler M, Goetze S, G\u00fcnther C, Hadaschik E, Homey B, Hunzelmann N, Kreuter A, Kunz M, Lippert U, Ludwig-Peitsch W, Pf\u00f6hler C, S\u00e1rdy M, Sticherling M, Worm M (2015)\nAllelic and copy-number variations of Fc\u03b3Rs affect granulocyte function and susceptibility for autoimmune blistering diseases.\nJ Autoimmun 61, 36-44.\nSchmidt M, Goebeler M (2015)\nImmunology of metal allergies.\nJDDG 13, 653-9.\nSchmieder A, Poppe M, Hametner C, Meyer-Schraml H, Schaarschmidt ML, Findeisen P, Benoit S, Bauer B, Schmid S, Goebeler M, Goerdt S, Ludwig-Peitsch WK (2015)\nImpact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study.\nArch Dermatol Res 307, 413-24.\nSommer M, Trautmann A, Stoevesandt J (2015)\nRelief of photoallergy: atorvastatin replacing simvastatin.\nJ Investig Allergol Clin Immunol 25, 138-40.\nStoevesandt J, Hosp C, Kerstan A, Trautmann A (2015)\nHymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective.\nAnn Allergy Asthma Immunol 114, 411-6.\nTeichert M, Stumpf C, Booken N, Wobser M, Nashan D, Hallermann C, Mogler C, M\u00fcller CS, Becker JC, Moritz RK, Andrulis M, Nicolay JP, Goerdt S, Thomas M, Klemke CD, Augustin HG, Felcht M (2015)\nAggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.\nExp Dermatol 24, 424-9.\nThode C, Woetmann A, Wandall HH, Carlsson MC, Qvortrup K, Kauczok CS, Wobser M, Printzlau A, Odum N, Dabelsteen S (2015)\nMalignant T Cells Secrete Galectins and Induce Epidermal Hyperproliferation and Disorganized Stratification in a Skin Model of Cutaneous T Cell Lymphoma.\nJ Invest Dermatol 135, 238-246.\nUgurel S, Loquai C, K\u00e4hler K, Hassel J, Berking C, Zimmer L, Haubitz I, Satzger I, M\u00fcller-Brenne T, Mikhaimer NC, Becker JC, Kilian KJ, Schadendorf D, Heinzerling L, Kaatz M, Utikal J, G\u00f6ppner D, Pf\u00f6hler C, Pflugfelder A, M\u00f6ssner R, Gutzmer R; Dermatologic Cooperative Oncology Group (DeCOG)(2015)\nA\n[Multicenter](/medien-kontakt/glossar/Multicenter/?cHash=c327ddb47a84bba25bc17a9ebe41ed45) DeCOG study on [Predictors](/medien-kontakt/glossar/Predictors/?cHash=4c4b240251db5939ebb2de5458c3e780) of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.\nAnn Oncol 26, 573-82.\nVaman V S A, Poppe H, Houben R, Grunewald TG, Goebeler M, Butt E(2015)\nLASP1, a Newly Identified Melanocytic Protein with a Possible Role in Melanin Release, but Not in Melanoma Progression.\nPLoS One 10:e0129219.\nWobser M, Bauer B, Goebeler M (2015)\nSubcutaneous nodule on the scrotum.\nJ Dtsch Dermatol Ges 13, 165-7.\nWobser M, Ernestus K, Hamm H (2015)\nPediatric dermatohistopathology - histopathology of skin diseases in newborns and infants.\nJ Dtsch Dermatol Ges 13, 535-48.\nWobser M, Roth S, Reinartz T, Rosenwald A, Goebeler M, Geissinger E (2015)\nCD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas.\nBr J Dermatol 172, 1573-80.\nZeller S, Lempert S, Goebeler M, Hamm H, Kolb-M\u00e4urer A (2015)\nCladosporium cladosporioides: a so far unidentified cause of white piedra.\nMycoses 58, 315-7.\nZ\u00f6rnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichm\u00fcller SB, J\u00e4ger D (2015)\nPrognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.\nInt J Cancer 136, 138-5.\nPublikationen 2014\nAdam C, Baeurle A, Brodsky JL, Wipf P, Schrama D, Becker JC, Houben R (2014)\nThe HSP70 Modulator MAL3-101 Inhibits Merkel Cell Carcinoma.\nPLoS ONE 9:e92041.\nAigner B, Ugurel S, Kaddu S, Becker JC. Kutane Sarkome (2014)\nUpdate ausgew\u00e4hlter Entit\u00e4ten fibrohistiozyt\u00e4rer und myofibrozyt\u00e4rer Morphologie.\nHautarzt 65, 614-622.\nAngermeyer S, Hesbacher S, Becker JC, Schrama D, Houben R (2014)\nResponse to Shuda et al.\nJ Invest Dermatol 134, 1481-2.\nBehle V, Hamm H (2014)\nDevelopmental abnormalities and nevi of the scalp.\nHautarzt 65, 1022-9.\nBehr DS, Peitsch WK, Hametner C, Lasitschka F, Houben R, Sch\u00f6nhaar K, Michel J, Dollt C, Goebeler M, Marx A, Goerdt S, Schmieder A (2014)\nPrognostic value of immune cell infiltration, tertiary lymphoid structures and pd-l1 expression in Merkel cell carcinomas.\nInt J Clin Exp Pathol 7, 7610-21.\nBenoit S, Goebeler M (2014)\nVasculitis in childhood - a dermatological approach.\nJ Dtsch Dermatol Ges 12, 124-9.\nBenoit S, Schlipf N, Hausser I, Fischer J, Hamm H (2014)\nWhite Sponge Nevus - A Rare Autosomal Dominant Keratinopathy.\nKlin Padiatr 226, 375-376.\nBrasch J, Becker D, Aberer W, Bircher A, Kr\u00e4nke B, Jung K, Przybilla B, Biedermann T, Werfel T, John SM, Elsner P, Diepgen T, Trautmann A, Merk HF, Fuchs T, Schnuch A (2014)\nGuideline contact dermatitis: S1-Guidelines of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG.\nAllergo J Int 23, 126-138.\nBuder K, Hamm H (2014)\nResidents' corner October 2014. Nail it! A bleeding tumour at the fingertip.\nEur J Dermatol 24, 637-8.\nBuder K, Hamm H. Residents' corner April 2014 (2014)\nNail it!: eye-catching nail folds.\nEur J Dermatol 24, 283-4.\nBuder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, Br\u00f6cker EB, Goebeler M, Buck AK, Becker JCn(2014)\nSomatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.\nBMC Cancer 14, 268.\nBuder K, Ruppert S, Trautmann A, Br\u00f6cker E-B, Goebeler M, Kerstan A (2014) Angiolymphoide Hyperplasie mit Eosinophilie und Morbus Kimura - ein klinischer und histopathologischer Vergleich.\nJ Dtsch Dermatol Ges 12, 224-8.\nBuder K, M\u00fcller PA, Beckmann G, Ugurel S, Br\u00f6cker EB, Becker JC (2014)\nDenileukin Diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell lymphoma (Mycosis fungoides): report of four cases.\nActa Derm Venereol 94, 94-96.\nChandran PA, Keller A, Weinmann L, Seida AA, Braun M, Andreev K, Fischer B, Horn E, Schwinn S, Junker M, Houben R, Dombrowski Y, Dietl J, Finotto S, W\u00f6lfl M, Meister G, Wischhusen J (2014)\nThe TGF-\u03b2-inducible miR-23a cluster attenuates IFN-\u03b3 levels and antigen-specific cytotoxicity in human CD8\u207aT cells.\nJ Leukoc Biol 96, 633-45.\nFredholm S, Gjerdrum LM, Willerslev-Olsen A, Petersen DL, Nielsen I\u00d8, Kauczok CS, Wobser M, Ralfkiaer U, Bonefeld CM, Wasik MA, Krejsgaard T, Geisler C, Ralfkiaer E, Gniadecki R, Woetmann A, Odum N (2014)\nSTAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res 34, 5277-86.\nGerstner S, Kneitz H, Br\u00f6cker EB, Trautmann A (2014)\nDifferentialdiagnose Angio\u00f6dem. Akut \u00f6demat\u00f6ses Skleromyx\u00f6dem.\nHautarzt 65, 454-7.\nGoldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG) (2014)\nUpstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.\nEur J Cancer 50, 406-10.\nGutzmer R, Hassel JC, K\u00e4hler KC, Loquai C, M\u00f6ssner R, Ugurel S, Zimmer L, f\u00fcr das Komitee \"Kutane Nebenwirkungen\" der ADO (2014)\nKutane Nebenwirkungen der medikament\u00f6sen Tumortherapie mit BRAF- und MEK-Inhibitoren.\nHautarzt 65, 582-89.\nHamm H, Wolff H (2014)\nBlickpunkt Kopfhaut.\nHautarzt 65, 1020-1.\nHamm, H (2014)\nImpact of Hyperhidrosis on Quality of Life and its Assessment.\nDermatol Clin 32, 467-76.\nHavlickova B, Weyandt GH (2014)\nTherapeutic management of anal eczema: an evidence-based review.\nInt J Clin Pract 68, 1388-99.\nHeiduschka G, Lill C, Seemann R, Brunner M, Schmid R, Houben R, Bigenzahn J, Thurnher D (2014)\nThe effect of resveratrol in combination with irradiation and chemotherapy.\nStrahlenther Onkol 190, 75-80.\nH\u00f6ger PH, Hamm H (2014)\nPsoriasis vulgaris bei Kinder und Jugendlichen.\nMonatsschr Kinderheilkd 162, 163-77.\nHouben R, Schmid CP, Maier M, Wobser M, Motschenbacher S, Becker JC, Vetter-Kauczok CS, Weyandt G, Hesbacher S, Haferkamp S (2014)\np53 Regulation by TRP2 Is Not Pervasive in Melanoma.\nPLoS ONE 9:e87440.\nHumbert P, Faivre B, V\u00e9ran Y, Debure C, Truchetet F, B\u00e9cherel PA, Plantin P, Kerihuel JC, Eming SA, Dissemond J, Weyandt G, Kaspar D, Smola H, Z\u00f6llner P, the CLEANSITE study group (2014)\nProtease-modulating polyacrylate-based hydrogel stimulates wound bed preparation in venous leg ulcers - a randomized controlled trial.\nJ Eur Acad Dermatol Venereol 28, 1742-50.\nKarademir F, Kerstan A, Hamm H (2014)\nAnetodermisches Pilomatrikom. Seltene Variante eines h\u00e4ufigen Adnextumors im Kindesalter.\nHautarzt 65, 59-62.\nKarl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M, Wajant H, Giner T (2014)\nTRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.\nCell Death Dis 5:e1444.\nKolb-M\u00e4urer A, Betz RC, Hamm H (2014)\nOdd-Looking Hair and Progressive Alopecia in Mother and Son.\nJAMA Dermatol 150, 567-8.\nKuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A, Amler S, Bonsmann G; The EUSCLE Co-Authors (u. a. Benoit S, Br\u00f6cker E) (2014)\nInfluence of Smoking on Disease Severity and Antimalarial Therapy in Cutaneous Lupus Erythematosus: Analysis of 1002 Patients from the EUSCLE Database.\nBr J Dermatol 171, 571-9.\nLeufke C, Leykauf J, Krunic D, Jauch A, Holtgreve-Grez, B\u00f6hm-Steuer B, Br\u00f6cker E-B, Mauch C, Utikal J, Hartschuh W, Purdie KJ, Boukamp P (2014)\nThe telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas.\nOncogene 33, 3506-18.\nPaulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, Seo A, Koelle DM, Madeleine MM, Bhatia S, Nakajima H, Sano S, Hardwick J, Disis ML, Cleary MA, Becker JC, Nghiem P (2014)\nDownregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.\nCancer Immunol Res 2, 1071-9.\nSchrama D, Groesser L, Ugurel S, Hafner C, Pastrana DV, Buck CB, Cerroni L, Theiler A, Becker JC (2014)\nPresence of Human Polyomavirus 6 in Mutation-Specific BRAF Inhibitor-Induced Epithelial Proliferations.\nJAMA Dermatol 150, 1180-6.\nSchrama D, Ugurel S, Sucker A, Ritter C, Zapatka M, Schadendorf D, Becker JC (2014)\nSTAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFN\u03b1 Therapy in Stage III Melanoma Patients.\nFront Med (Lausanne) 1, 47.\nSeitz CS, Brockow K, Hain J, Trautmann A (2014)\nNon-steroidal anti-inflammatory drug hypersensitivity: association with elevated basal serum tryptase?\nAllergy Asthma Clin Immunol 10, 19.\nStarke J, Wehrle-Haller B, Friedl P (2014)\nPlasticity of the actin cytoskeleton in response to extracellular matrix nanostructure and dimensionality.\nBiochem Soc Trans. 42, 1356-66.\nStoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A (2014)\nAngiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy buildup phase.\nClin Exp Allergy 44, 747-55.\nStoevesandt J, Hosp C, Kerstan A, Trautmann A (2014)\nRisikostratifizierung systemischer allergischer Reaktionen w\u00e4hrend Einleitung der spezifischen Immuntherapie mit Bienen- und Wespengift.\nJ Dtsch Dermatol Ges 12, 244-56.\nTrautmann A, Seitz CS, Stoevesandt J, Kerstan A (2014)\nAminopenicillin-associated exanthem: lymphocyte transformation testing revisited.\nClin Exp Allergy 44, 1531-8.\nUgurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pf\u00f6hler C, Schiller M, Hauschild A, Hein R, K\u00e4mpgen E, Kellner I, Leverkus M, Becker JC, Str\u00f6bel P, Schadendorf D (2014)\nNeo-adjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase-II DeCOG trial with long-term follow-up.\nClin Cancer Res 20, 499-510.\nVan Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG) (2014)\nThe Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma.\nCancer Discov 4, 94-109.\nWaldenburger S, Vogel U, Goebeler M, Kolb-M\u00e4urer A (2014)\nAmbulant erworbene Hautinfektionen durch Staphylococcus aureus: spielt das Toxin Panton-Valentine-Leukozidin eine Rolle?\nJ Dtsch Dermatol Ges 12:59-67.\nWeishaupt J, Kolb-M\u00e4urer A, Lempert S, Nenoff P, Uhrla\u00df S, Hamm H, Goebeler M (2014)\nA different kind of hedgehog pathway: tinea manus due to Trichophyton erinacei transmitted by an African pygmy hedgehog (Atelerix albiventris).\nMycoses 57, 125-7.\nWieshuber C, Stoevesandt J, Trautmann A (2014)\nThe needle in the haystack: allergic anaphylaxis caused by the local anesthetic articaine.\nEur Ann Allergy Clin Immunol 46, 38-40.\nWobser M, Hamm H (2014)\nTeleangiectasia macularis eruptiva perstans with congenital onset in a 5-year-old girl.\nClin Dermatol 2:144-146.\nKontakt, \u00d6ffnungszeiten, Sprechzeiten\nTerminvereinbarung Poliklinik\nTel. +49 931 201-26714\nMontag bis Donnerstag\n08:00 Uhr bis 10:00 Uhr und\n13:00 Uhr bis 16:00 Uhr\nFreitag\n08:00 Uhr bis 10:00 Uhr und\n13:00 Uhr bis 15:00 Uhr\nTerminvereinbarung Privatambulanz\nMontag bis Freitag\n08:00 Uhr bis 12:00 Uhr\nMargit K\u00f6rner\nTel. +49 931 201-26354\nTelefon\nPforte\n+49 931 201-26710\nDirektor\nProf. Dr. med. Matthias Goebeler\nSekretariat\nGudrun Braun\n+49 931 201-26351\nStudierendenangelegenheiten\nUte D\u00fcchs\n+49 931 201-26353\nAnschrift\nKlinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie | Josef-Schneider-Stra\u00dfe 2 | Haus D8 | 97080 W\u00fcrzburg | Deutschland", "language": null, "image": "/typo3conf/ext/ukw_sitepackage/Resources/Public/Images/logo_ukw_og.jpg", "pagetype": null, "links": ["#", "https://www.ukw.de/en/health-in-focus/", "https://www.ukw.de/ru/", "/hautklinik/", "/", "/", "https://www.ukw.de/en/health-in-focus/", "https://www.ukw.de/ru/", "/kliniken-zentren/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/chirurgie-i/startseite/", "/anaesthesie/startseite/", "/augenklinik/startseite/", "/chirurgie-i/startseite/", "/chirurgie-ii/startseite/", "/medizinische-klinik-i/endokrinologie/startseite/", "/frauenklinik/startseite/", "/medizinische-klinik-ii/gastroenterologie/startseite/", "/chirurgie-i/schwerpunkte/gefaesschirurgie-und-endovaskulaere-chirurgie/", "/gerinnungsambulanz/startseite/", "/medizinische-klinik-ii/haematologie/startseite/", "/chirurgie-ii/startseite/", "/hautklinik/startseite/", "/medizinische-klinik-ii/hepatologie/startseite/", "/herz-thorax-chirurgie/startseite/", "/hno-klinik/startseite/", "/medizinische-klinik-ii/infektiologie/startseite/", "/medizinische-klinik-i/intensiv-und-notfallmedizin/startseite/", "/medizinische-klinik-ii/internistische-onkologie/startseite/", "/medizinische-klinik-i/kardiologie/startseite/", "/kieferorthopaedie/startseite/", "/chirurgie-i/schwerpunkte/kinderchirurgie/", "/kinderklinik/startseite/", "/kinder-und-jugendpsychiatrie/startseite/", "/medizinische-klinik-i/startseite/", "/medizinische-klinik-ii/startseite/", "/mund-kiefer-und-plastische-gesichtschirurgie/startseite/", "/medizinische-klinik-i/nephrologie/startseite/", "/neurochirurgie/startseite/", "/neurologie/startseite/", "/neuroradiologie/startseite/", "/nuklearmedizin/startseite/", "/im-notfall/", "/medizinische-klinik-i/pneumologie/startseite/", "/palliativmedizin/startseite/", "/medizinische-klinik-ii/psychosomatische-medizin/startseite/", "/psychiatrie/startseite/", "/radiologie/startseite/", "/medizinische-klinik-ii/rheumatologie-immunologie/startseite/", "/medizinische-klinik-ii/zentrum-fuer-allogene-stammzelltherapien/startseite/", "/strahlentherapie-und-radioonkologie/startseite/", "/transfusionsmedizin/startseite/", "/chirurgie-i/startseite/", "/chirurgie-ii/startseite/", "/urologie/startseite/", "/zahnaerztliche-prothetik/startseite/", "/zahnerhaltung-und-parodontologie/startseite/", "/kliniken-zentren/gebaeudekomplexe/", "/kliniken-zentren/gebaeudekomplexe/", "/gebaeudekomplexe/haut-frauen-und-kinderklinik/haut-frauen-und-kinderklinik/", "/gebaeudekomplexe/kopfkliniken-kkl/kopfkliniken-kkl/", "/gebaeudekomplexe/zentrum-fuer-psychische-gesundheit-zep/zentrum-fuer-psychische-gesundheit-zep/", "/gebaeudekomplexe/zentrum-fuer-zahn-mund-und-kiefergesundheit/zentrum-fuer-zahn-mund-und-kiefergesundheit-zmkg/", "/gebaeudekomplexe/zentrum-fuer-innere-medizin-zim/zentrum-fuer-innere-medizin/", "/gebaeudekomplexe/zentrum-fuer-operative-medizin-zom/zentrum-fuer-operative-medizin-zom/", "/gebaeudekomplexe/zentrum-fuer-radiologie-zrad/zentrum-fuer-radiologie-zrad/", "/kliniken-zentren/interdisziplinaere-forschungszentren/", "/kliniken-zentren/interdisziplinaere-forschungszentren/", "http://https://www.med.uni-wuerzburg.de/ccc/startseite/", "/behandlungszentren/dzhi/startseite/", "/interdisziplinaere-einrichtungen/interdisziplinaere-biomaterial-und-datenbank-wuerzburg/startseite/", "/interdisziplinaere-einrichtungen/izkf/startseite/", "/behandlungszentren/muskuloskelettales-centrum-wuerzburg-mcw/startseite/", "/interdisziplinaere-einrichtungen/zentrale-fuer-klinische-studien-zksw/startseite/", "/behandlungszentren/zentrum-fuer-experimentelle-molekulare-medizin-zemm/startseite/", "/forschung-lehre/zentrum-fuer-psychische-gesundheit-zep/zentrum-fuer-psychische-gesundheit-zep/", "/behandlungszentren/biozentrum-universitaet-wuerzburg/startseite/", "/behandlungszentren/fraunhofer-translationszentrum-tzkme/startseite/", "/behandlungszentren/rudolf-virchow-zentrum/startseite/", "/forschung-lehre/zentrum-fuer-infektionsforschung-zinf/zentrum-fuer-infektionsforschung/", "/behandlungszentren/zentrum-fuer-vorsprachliche-entwicklung-und-entwicklungsstoerungen-zves/startseite/", "/kliniken-zentren/behandlungszentren/", "/kliniken-zentren/behandlungszentren/", "/behandlungszentren/adipositaszentrum/startseite/", "/behandlungszentren/allergiezentrum-mainfranken/startseite/", "/behandlungszentren/brustkrebs-und-brustzentrum/startseite/", "http://https://www.med.uni-wuerzburg.de/ccc/startseite/", "/hno-klinik/schwerpunkte/hoerzentrum-chc/", "/behandlungszentren/dzhi/startseite/", "/behandlungszentren/fruehdiagnosezentrum-sozialpaediatrisches-zentrum/startseite/", "/behandlungszentren/gynaekologisches-krebszentrum/startseite/", "/behandlungszentren/hautkrebszentrum/startseite/", "/behandlungszentren/herzzentrum-wuerzburg/startseite/", "/behandlungszentren/thoraxzentrum-mainfranken-itzm/startseite/", "/behandlungszentren/interdisziplinaeres-zentrum-fuer-angsterkrankungen-iza/startseite/", "/behandlungszentren/interdisziplinaeres-zentrum-fuer-gesunden-schlaf-izgs/startseite/", "/behandlungszentren/interdisziplinaeres-zentrum-fuer-lkg/startseite/", "/palliativmedizin/startseite/", "/behandlungszentren/interdisziplinaeres-zentrum-fuer-stimme-und-schlucken-izss/startseite/", "/behandlungszentren/kinderonkologisches-zentrum/startseite/", "/behandlungszentren/kinderwunschzentrum/startseite/", "/behandlungszentren/kopf-hals-tumorzentrum/startseite/", "/behandlungszentren/leberzentrum/startseite/", "/behandlungszentren/muskuloskelettales-centrum-wuerzburg-mcw/startseite/", "/behandlungszentren/neuromuskulaeres-zentrum/startseite/", "/behandlungszentren/neuroonkologisches-tumorzentrum-ntz/startseite/", "/behandlungszentren/onkologisches-zentrum/startseite/", "/behandlungszentren/onkologisches-zentrum/startseite/", "/behandlungszentren/perinatalzentrum-pnz/startseite/", "/behandlungszentren/peritonealkarzinosezentrum/startseite/", "/behandlungszentren/prostatakrebszentrum/startseite/", "/behandlungszentren/regionales-strahlenschutzzentrum-rsz/startseite/", "/behandlungszentren/rheumazentrum-wuerzburg/startseite/", "/behandlungszentren/sarkomzentrum/startseite/", "/behandlungszentren/schaedelbasiszentrum/startseite/", "/behandlungszentren/schlaganfallzentrum/startseite/", "/behandlungszentren/stammzelltransplantationszentrum/startseite/", "/behandlungszentren/sueddeutsches-brustwandzentrum-sbwz/startseite/", "/behandlungszentren/transplantationszentrum/startseite/", "/behandlungszentren/ueberregionales-traumazentrum/startseite/", "/behandlungszentren/viszeralonkologisches-zentrum/startseite/", "/behandlungszentren/who-rempan-zentrum/startseite/", "/behandlungszentren/schilddruesenzentrum-wuerzburg/startseite/", "/behandlungszentren/zahnunfallzentrum/startseite/", "/behandlungszentren/zentrum-fuer-interdisziplinaere-schmerzmedizin/startseite/", "/behandlungszentren/zentrum-fuer-neuroendokrine-tumoren-enets/startseite/", "/behandlungszentren/zentrum-fuer-seltene-erkrankungen-zese/startseite/", "/behandlungszentren/zentrum-fuer-seltene-erkrankungen-zese/startseite/", "/behandlungszentren/christiane-herzog-zentrum-fuer-mukoviszidose-unterfranken/startseite/", "/behandlungszentren/sarkoidosezentrum/startseite/", "/behandlungszentren/wuerzburger-zentrum-fuer-neurofibromatosen-wznf/startseite/", "/behandlungszentren/zentrum-fuer-achalasie-und-andere-oesophagusmotilitaetsstoerungen/startseite/", "/behandlungszentren/zentrum-fuer-blasenbildende-autoimmundermatosen/startseite/", "/behandlungszentren/zentrum-fuer-endokrine-tumore-zet/startseite/", "/behandlungszentren/zentrum-fuer-kongenitale-katarakt/startseite/", "/behandlungszentren/zentrum-fuer-maligne-hyperthermie/startseite/", "/behandlungszentren/zentrum-fuer-das-multiple-myelom/startseite/", "/behandlungszentren/zentrum-fuer-primaere-immundefekte-und-autoinflammatorische-erkrankungen/startseite/", "/behandlungszentren/zentrum-fuer-seltene-bewegungsstoerungen/startseite/", "/behandlungszentren/zentrum-fuer-seltene-neuromuskulaere-erkrankungen/startseite/", "/behandlungszentren/zentrum-fuer-vorsprachliche-entwicklung-und-entwicklungsstoerungen-zves/startseite/", "/behandlungszentren/zentrum-fuer-zellulaere-immuntherapie-zenith/startseite/", "/behandlungszentren/zentrum-fuer-psychische-gesundheit-zep/startseite/", "/gebaeudekomplexe/zentrum-fuer-innere-medizin-zim/zentrum-fuer-innere-medizin/", "/gebaeudekomplexe/zentrum-fuer-operative-medizin-zom/zentrum-fuer-operative-medizin-zom/", "/gebaeudekomplexe/zentrum-fuer-radiologie-zrad/zentrum-fuer-radiologie-zrad/", "/forschung/forschungseinrichtungen/", "/kliniken-zentren/netzwerke/", "/kliniken-zentren/netzwerke/", "/netzwerke/herzinfarktnetz-mainfranken/startseite/", "/netzwerke/netzwerk-hoffnung/startseite/", "/netzwerke/transregionales-netzwerk-fuer-schlaganfallintervention-mit-telemedizin-transit-stroke/startseite/", "/netzwerke/traumanetzwerk-nordbayern-wuerzburg/startseite/", "/netzwerke/antimicrobial-stewardship-netzwerk-mainfranken-ams-man/startseite/", "/kliniken-zentren/servicebereiche-und-ansprechpartner/", "/kliniken-zentren/servicebereiche-und-ansprechpartner/", "/ausbildung-fort-und-weiterbildung/akademie/startseite/", "/zentrale-einrichtungen/apotheke/startseite/", "/zentrale-einrichtungen/betriebsaerztlicher-dienst/startseite/", "/zentrale-einrichtungen/beratungsstelle-fuer-beschaeftigte-des-ukw/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/beauftragte-kommissionen-und-arbeitsgruppen/", "/ueber-das-ukw/klinikumsleitung/vorstand/beauftragte-kommissionen-und-arbeitsgruppen/", "/zentrale-einrichtungen/klinisches-ethikkomitee/startseite/", "/zentrale-einrichtungen/krankenhaushygiene-und-antimicrobial-stewardship/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/stabsstelle-medizinsicherheit/", "/zentrale-einrichtungen/patientenservice-und-medizincontrolling/startseite/", "/zentrale-einrichtungen/personalrat/startseite/", "/patienten-und-besucher/unser-pflegedienst/unser-pflegedienst/", "/zentrale-einrichtungen/physiotherapie/physiotherapie/", "/patienten-und-besucher/qualitaetsmanagement/startseite/", "/zentrale-einrichtungen/seelsorge/startseite/", "/zentrale-einrichtungen/servicezentrum-medizin-informatik-smi/startseite/", "/ausbildung-fort-und-weiterbildung/staatliches-berufliches-schulzentrum-fuer-gesundheitsberufe/startseite/", "/zentrale-einrichtungen/zentrallabor/startseite/", "/zentrale-einrichtungen/aufbereitungseinheit-fuer-medizinprodukte/startseite/", "/patienten-besucher/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/patienten-besucher/veranstaltungskalender/", "/patienten-besucher/anreise/", "/patienten-besucher/anreise/", "/patienten-besucher/anreise/lageplan-universitaetsklinikum-wuerzburg/", "/patienten-besucher/anreise/anreise-mit-oeffentlichen-verkehrsmitteln/", "/patienten-besucher/anreise/anreise-mit-dem-pkw/", "/patienten-besucher/anreise/parkmoeglichkeiten/", "/patienten-besucher/service-abc/", "/patienten-besucher/ihr-aufenthalt-am-klinikum/", "/patienten-besucher/gastronomie-am-klinikum-speiseplaene/", "/patienten-besucher/ambulante-behandlung/", "/patienten-besucher/unser-entlassmanagement/", "/patienten-und-besucher/unser-pflegedienst/unser-pflegedienst/", "/patienten-und-besucher/qualitaetsmanagement/startseite/", "/patienten-besucher/kinder/", "/patienten-besucher/altersgerechte-uniklinik/", "/patienten-besucher/inklusion/", "/patienten-besucher/unser-international-office/", "/patienten-besucher/soziale-kontakte/", "/patienten-besucher/soziale-kontakte/", "/zentrale-einrichtungen/seelsorge/startseite/", "/patienten-und-besucher/unser-pflegedienst/ansprechpartner/sozialdienst-und-pflegeberatung/", "/patienten-besucher/soziale-kontakte/patientenfuersprecher/", "/patienten-besucher/soziale-kontakte/gruene-damen-und-herren/", "/patienten-besucher/selbsthilfe/", "/patienten-besucher/selbsthilfe/", "/patienten-besucher/ihr-gutes-recht/", "/patienten-besucher/patientenanfragen/", "/patienten-und-besucher/lba/lob-beschwerden-anregungen/", "/patienten-besucher/patientengruss/", "/transfusionsmedizin/schwerpunkte/blutspende/blut-und-thrombozyten-spenden-am-uniklinikum-wie-geht-das/", "/patienten-besucher/krankenhaushygiene/", "/patienten-besucher/ratgeber-und-leitfaeden/", "/zuweiser/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/zuweiser/informationen-fuer-zuweisende-kolleginnen-und-kollegen/", "/zuweiser/kommunikationsportal/", "/kliniksuche/", "https://www.ukw.de/?id=12627&no_cache=1&tx_events2_events%5Baction%5D=listSearchResults&tx_events2_events%5Bcontroller%5D=Day&tx_events2_events%5Bsearch%5D%5&tx_events2_events%5Bsearch%5D%5Btargetgroup%5D=2", "/patienten-und-besucher/qualitaetsmanagement/startseite/", "/forschung/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/forschung/forschungsprofil/", "/forschung/klinische-forschung/", "/forschung/klinische-forschung/", "/anaesthesie/forschung/", "/augenklinik/forschung/", "/chirurgie-i/forschung/", "/chirurgie-ii/forschung/", "/behandlungszentren/dzhi/forschung/", "/forschung-lehre/institut-fuer-experimentelle-biomedizin/experimentelle-biomedizin-lehrstuhl-i/forschung/", "/forschung-lehre/institut-fuer-experimentelle-biomedizin/experimentelle-biomedizin-lehrstuhl-ii/forschung/", "/forschung-lehre/forensik/forschung/", "/frauenklinik/forschung/", "/medizinische-klinik-ii/gastroenterologie/forschung/", "/hautklinik/forschung/", "/medizinische-klinik-ii/hepatologie/forschung/", "/herz-thorax-chirurgie/forschung/", "/hno-klinik/forschung/", "/medizinische-klinik-i/intensiv-und-notfallmedizin/forschung/", "/medizinische-klinik-ii/internistische-onkologie/forschung/", "/medizinische-klinik-i/kardiologie/forschung/", "/kinderklinik/forschung/", "/medizinische-klinik-ii/forschung/", "/mund-kiefer-und-plastische-gesichtschirurgie/forschung/", "/medizinische-klinik-ii/abteilung-molekulare-innere-medizin/forschung/", "/medizinische-klinik-i/nephrologie/forschung/", "/neurochirurgie/forschung/", "/neurologie/forschung/", "/neuroradiologie/forschung/", "/nuklearmedizin/forschung/", "/palliativmedizin/forschung/", "/zahnerhaltung-und-parodontologie/forschung/", "/forschung-psychiatrie/forschung-in-der-psychiatrie/", "/medizinische-klinik-ii/psychosomatische-medizin/forschung/", "/radiologie/forschung/", "/redares-projekt/startseite/", "/medizinische-klinik-ii/rheumatologie-immunologie/forschung/", "/strahlentherapie-und-radioonkologie/forschung/", "/transfusionsmedizin/forschung/", "/urologie/forschung/", "/zahnaerztliche-prothetik/forschung/", "/zahnerhaltung-und-parodontologie/forschung/", "/behandlungszentren/zentrum-fuer-interdisziplinaere-schmerzmedizin/forschung/", "/forschung/forschungseinrichtungen/", "/forschung/interdisziplinaere-forschungszentren/", "/forschung/interdisziplinaere-forschungszentren/", "http://https://www.med.uni-wuerzburg.de/ccc/startseite/", "/behandlungszentren/dzhi/startseite/", "/interdisziplinaere-einrichtungen/interdisziplinaere-biomaterial-und-datenbank-wuerzburg/startseite/", "/interdisziplinaere-einrichtungen/izkf/startseite/", "/behandlungszentren/muskuloskelettales-centrum-wuerzburg-mcw/startseite/", "/behandlungszentren/zentrum-fuer-experimentelle-molekulare-medizin-zemm/startseite/", "/interdisziplinaere-einrichtungen/zentrale-fuer-klinische-studien-zksw/startseite/", "/behandlungszentren/biozentrum-universitaet-wuerzburg/startseite/", "/behandlungszentren/fraunhofer-translationszentrum-tzkme/startseite/", "/behandlungszentren/rudolf-virchow-zentrum/startseite/", "/gebaeudekomplexe/zentrum-fuer-psychische-gesundheit-zep/zentrum-fuer-psychische-gesundheit-zep/", "/forschung-lehre/zentrum-fuer-infektionsforschung-zinf/zentrum-fuer-infektionsforschung/", "/behandlungszentren/zentrum-fuer-vorsprachliche-entwicklung-und-entwicklungsstoerungen-zves/startseite/", "/forschung/forschungsinfrastruktur/", "/forschung/forschungsverbuende/", "/forschung/chancengleichheit/", "/forschung/chancengleichheit/", "/forschung/chancengleichheit/gleichstellung/", "/forschung/chancengleichheit/women-in-science/", "/forschung/links/", "/lehre/", "/lehre/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/lehre/studiengaenge-der-medizinischen-fakultaet/", "/karriere/duales-studium/", "http://www.lehrklinik.medizin.uni-wuerzburg.de/startseite/", "/lehre/lehrkrankenhaeuser/", "/lehre/lehrkrankenhaeuser/", "http://www.ckbm.de/ckbm/index.php", "http://www.klinikum-ab-alz.de/", "https://klinikum-msp.de/kliniken.html", "http://www.kwm-klinikum.de/", "https://www.anregiomed.de/medizin-und-pflege/klinik-rothenburg", "http://www.leopoldina-krankenhaus.com/home/", "/lehre/praktisches-jahr-pj/", "/forschung-lehre/wuerzburger-philosophicum/startseite/", "/karriere/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/karriere/stellenangebote/", "/karriere/arbeitgebervorteile/", "/karriere/arbeitgebervorteile/lebenswertes-wuerzburg/", "/karriere/burgerdate-mit-unseren-ausbilderinnen-und-ausbildern/", "/karriere-am-ukw/karriere-in-der-pflege/karriere-in-der-pflege/", "/flex4ukw/", "/karriere/initiativbewerbung-pflege/", "/karriere-am-ukw/1000-moeglichkeiten/1000-moeglichkeiten-fuer-dich/", "/karriere/ausbildung-fsj-praktikum/", "/karriere/ausbildung-fsj-praktikum/", "/karriere/ausbildung-fsj-praktikum/pflege-mfa-zfa-otaata-mta/", "/karriere/ausbildung-fsj-praktikum/physiotherapie-massage/", "/karriere/ausbildung-fsj-praktikum/mfa-schwerpunkt-drg-kaufleute-fuer-bueromanagement-oder-im-gesundheitswesen/", "/karriere/ausbildung-fsj-praktikum/fachkraft-fuer-lagerlogistik-elektroniker-anlagenmechaniker-tierpfleger/", "/karriere/ausbildung-fsj-praktikum/it/", "/karriere/ausbildung-fsj-praktikum/kueche/", "/karriere/duales-studium/", "/karriere/duales-studium/", "/karriere/duales-studium/studium-an-der-universitaet-wuerzburg/", "/karriere/duales-studium/duales-studium/", "/karriere/fort-und-weiterbildung/", "/ueber-das-ukw/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "javascript:void(0);", "/ueber-das-ukw/begruessung-durch-den-vorstand/", "/ueber-das-ukw/medizin-und-wissenschaft-auf-hoechstem-niveau/", "/ueber-das-ukw/wofuer-wir-stehen-unser-leitbild/", "/ueber-das-ukw/geschichte/", "/ueber-das-ukw/geschichte/", "/ueber-uns/100-jahre-luitpold-campus/startseite/", "/ueber-das-ukw/geschichte/forschung-mit-tradition/", "/ueber-das-ukw/preistraeger-und-herausragende-persoenlichkeiten/", "/ueber-das-ukw/preistraeger-und-herausragende-persoenlichkeiten/", "/ueber-das-ukw/preistraeger-und-herausragende-persoenlichkeiten/abschied-von-prof-dr-med-georg-ertl/", "/ueber-das-ukw/das-klinikum-in-zahlen/", "/ueber-das-ukw/klinikumsleitung/", "/ueber-das-ukw/klinikumsleitung/", "/ueber-das-ukw/klinikumsleitung/aufsichtsrat/", "/ueber-das-ukw/klinikumsleitung/vorstand/", "/ueber-das-ukw/klinikumsleitung/vorstand/", "/ueber-das-ukw/klinikumsleitung/vorstand/der-vorstand-auf-einen-blick/", "/ueber-das-ukw/klinikumsleitung/vorstand/aerztliche-direktion/", "/ueber-das-ukw/klinikumsleitung/vorstand/zentrale-einrichtungen/", "/ueber-das-ukw/klinikumsleitung/vorstand/zentrale-einrichtungen/", "/ausbildung-fort-und-weiterbildung/akademie/startseite/", "/zentrale-einrichtungen/apotheke/startseite/", "/zentrale-einrichtungen/betriebsaerztlicher-dienst/startseite/", "/interdisziplinaere-einrichtungen/interdisziplinaere-biomaterial-und-datenbank-wuerzburg/startseite/", "/interdisziplinaere-einrichtungen/zentrale-fuer-klinische-studien-zksw/startseite/", "/zentrale-einrichtungen/krankenhaushygiene-und-antimicrobial-stewardship/startseite/", "/zentrale-einrichtungen/servicezentrum-medizin-informatik-smi/startseite/", "/zentrale-einrichtungen/aufbereitungseinheit-fuer-medizinprodukte/startseite/", "/zentrale-einrichtungen/zentrallabor/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/", "/zentrale-einrichtungen/beratungsstelle-fuer-beschaeftigte-des-ukw/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/stabsstelle-datenschutz-compliance-und-organisation/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/stabsstelle-grosse-baumassnahmen/", "/medien-kontakt/presse/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/stabsstelle-medizinsicherheit/", "/patienten-und-besucher/qualitaetsmanagement/startseite/", "/klinikumsleitung-und-verwaltung/stabsstelle-nachhaltigkeit/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/beauftragte-kommissionen-und-arbeitsgruppen/", "/ueber-das-ukw/klinikumsleitung/klinikumskonferenz/", "/ueber-das-ukw/klinikumsleitung/dekanat-der-medizinischen-fakultaet/", "/zentrale-einrichtungen/pflegedirektion/startseite/", "/ueber-das-ukw/klinikumsleitung/verwaltung/", "/ueber-das-ukw/klinikumsleitung/verwaltung/", "/ueber-das-ukw/klinikumsleitung/verwaltung/stabsstelle-interne-revision/", "/ueber-das-ukw/klinikumsleitung/verwaltung/geschaeftsbereich-1-forschungsfoerderung-und-drittmittelmanagement/", "/ueber-das-ukw/klinikumsleitung/verwaltung/geschaeftsbereich-2-personal/", "/ueber-das-ukw/klinikumsleitung/verwaltung/geschaeftsbereich-3-finanzen-und-controlling/", "/ueber-das-ukw/klinikumsleitung/verwaltung/geschaeftsbereich-4-einkauf-logistik-liegenschaften-dienstleistungen/", "/ueber-das-ukw/klinikumsleitung/verwaltung/geschaeftsbereich-5-technik-und-bau/", "/ueber-das-ukw/klinikumsleitung/verwaltung/stabsstelle-interne-revision/", "/ueber-das-ukw/klinikumsleitung/verwaltung/stabsstelle-recht/", "/ueber-das-ukw/klinikumsleitung/verwaltung/", "/ueber-das-ukw/klinikumsleitung/vorstand/zentrale-einrichtungen/", "/ueber-das-ukw/klinikumsleitung/vorstand/zentrale-einrichtungen/", "/ausbildung-fort-und-weiterbildung/akademie/startseite/", "/zentrale-einrichtungen/apotheke/startseite/", "/zentrale-einrichtungen/betriebsaerztlicher-dienst/startseite/", "/interdisziplinaere-einrichtungen/interdisziplinaere-biomaterial-und-datenbank-wuerzburg/startseite/", "/interdisziplinaere-einrichtungen/zentrale-fuer-klinische-studien-zksw/startseite/", "/zentrale-einrichtungen/krankenhaushygiene-und-antimicrobial-stewardship/startseite/", "/zentrale-einrichtungen/servicezentrum-medizin-informatik-smi/startseite/", "/zentrale-einrichtungen/aufbereitungseinheit-fuer-medizinprodukte/startseite/", "/zentrale-einrichtungen/zentrallabor/startseite/", "/ueber-das-ukw/servicebereiche-und-ansprechpartner/", "/ueber-das-ukw/servicebereiche-und-ansprechpartner/", "/ausbildung-fort-und-weiterbildung/akademie/startseite/", "/zentrale-einrichtungen/apotheke/startseite/", "/zentrale-einrichtungen/betriebsaerztlicher-dienst/startseite/", "/zentrale-einrichtungen/beratungsstelle-fuer-beschaeftigte-des-ukw/startseite/", "/ueber-das-ukw/klinikumsleitung/vorstand/stabsstellen-des-vorstands/", "/ueber-das-ukw/klinikumsleitung/vorstand/beauftragte-kommissionen-und-arbeitsgruppen/", "/ueber-das-ukw/klinikumsleitung/vorstand/beauftragte-kommissionen-und-arbeitsgruppen/", "/zentrale-einrichtungen/klinisches-ethikkomitee/startseite/", "/zentrale-einrichtungen/krankenhaushygiene-und-antimicrobial-stewardship/startseite/", "/zentrale-einrichtungen/patientenservice-und-medizincontrolling/startseite/", "/zentrale-einrichtungen/personalrat/startseite/", "/patienten-und-besucher/unser-pflegedienst/unser-pflegedienst/", "/zentrale-einrichtungen/physiotherapie/physiotherapie/", "/patienten-und-besucher/qualitaetsmanagement/startseite/", "/zentrale-einrichtungen/schwerbehindertenvertretung/startseite/", "/zentrale-einrichtungen/seelsorge/startseite/", "/zentrale-einrichtungen/servicezentrum-medizin-informatik-smi/startseite/", "/ausbildung-fort-und-weiterbildung/staatliches-berufliches-schulzentrum-fuer-gesundheitsberufe/startseite/", "/zentrale-einrichtungen/zentrallabor/startseite/", "/ueber-das-ukw/geschaefts-und-jahresberichte/", "/ueber-das-ukw/amtliche-veroeffentlichungen-und-satzungen/", "/medien-kontakt/presse/mediathek/", "/medien-kontakt/presse/magazine/", "/medien-kontakt/spenden/", "/ueber-das-ukw/foerdervereine-stiftungen/", "/ueber-uns/bauprojekte-am-ukw/ausblick/", "/startseite/", "/kliniken-zentren/", "/kliniken-zentren/kliniken-und-klinische-schwerpunkte/", "/hautklinik/startseite/", "/hautklinik/hautaerztliche-notfaelle/", "/hautklinik/startseite/", "/hautklinik/team/", "/hautklinik/schwerpunkte/", "/hautklinik/schwerpunkte/hautkrebs/", "/hautklinik/schwerpunkte/hautkrebs/melanom/", "/hautklinik/schwerpunkte/hautkrebs/heller-hautkrebs/", "/hautklinik/schwerpunkte/hautkrebs/kutane-lymphome/", "/hautklinik/schwerpunkte/hautkrebs/seltene-hauttumoren/", "/hautklinik/schwerpunkte/entzuendliche-erkrankungen/", "/hautklinik/schwerpunkte/entzuendliche-erkrankungen/schuppenflechte-psoriasis/", "/hautklinik/schwerpunkte/entzuendliche-erkrankungen/acne-inversa/", "/hautklinik/schwerpunkte/autoimmunerkrankungen-der-haut/", "/hautklinik/schwerpunkte/autoimmunerkrankungen-der-haut/blasenbildende-autoimmunerkrankungen/", "/hautklinik/schwerpunkte/autoimmunerkrankungen-der-haut/kollagenosen/", "/hautklinik/schwerpunkte/autoimmunerkrankungen-der-haut/vaskulitiden/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/arzneimittelreaktionen/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/bienen-und-wespengiftallergien/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/neurodermitis-und-andere-ekzemkrankheiten/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/nahrungsmittelallergien/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/angiooedeme/", "/hautklinik/schwerpunkte/allergien-und-allergieassoziierte-erkrankungen/urtikaria-nesselsucht/", "/hautklinik/schwerpunkte/hauterkrankungen-im-kindesalter/", "/hautklinik/schwerpunkte/hauterkrankungen-im-kindesalter/blutschwaemme-haemangiome-im-kindesalter/", "/hautklinik/schwerpunkte/hauterkrankungen-im-kindesalter/muttermale-naevi/", "/hautklinik/schwerpunkte/hauterkrankungen-im-kindesalter/melanozytaere-naevi/", "/hautklinik/schwerpunkte/hauterkrankungen-im-kindesalter/erbliche-hauterkrankungen-genodermatosen/", "/hautklinik/schwerpunkte/netzwerk-chronische-wunde-ukw/", "/hautklinik/schwerpunkte/spezielle-therapien/", "/hautklinik/schwerpunkte/spezielle-therapien/uv-licht-therapie-und-photodynamische-therapie-pdt/", "/hautklinik/schwerpunkte/spezielle-therapien/lasertherapie/", "/hautklinik/schwerpunkte/spezielle-therapien/dermatochirurgie/", "/hautklinik/stationaere-behandlung/", "/hautklinik/tagesklinik/", "/hautklinik/ambulante-behandlung/", "/hautklinik/diagnostische-labore/", "/hautklinik/diagnostische-labore/laborbereiche/", "/hautklinik/diagnostische-labore/formulare/", "/hautklinik/diagnostische-labore/zertifikate-und-akkreditierungen/", "/hautklinik/diagnostische-labore/leistungsverzeichnis/", "/hautklinik/forschung/", "/hautklinik/forschung/translationale-tumorimmunologie-und-immunotherapie/", "/hautklinik/forschung/molekulare-dermatologie/", "/hautklinik/forschung/molekulare-dermatologie/kontakt-und-medikamentenallergie/", "/hautklinik/forschung/molekulare-dermatologie/gefaesserhaltung-entzuendung-und-reorganisation/", "/hautklinik/forschung/molekulare-dermatologie/acne-inversa/", "/hautklinik/forschung/publikationen/", "/hautklinik/lehre-weiter-und-fortbildung/", "/hautklinik/lehre-weiter-und-fortbildung/studium-und-lehre/", "/hautklinik/lehre-weiter-und-fortbildung/weiterbildung/", "/hautklinik/lehre-weiter-und-fortbildung/fortbildungen/", "/hautklinik/netzwerke/", "/hautklinik/anreise/", null, "/medien-kontakt/glossar/Dermatologie/?cHash=e5d70f5710821089595b6ddf4aecfed7", "/medien-kontakt/glossar/Venerologie/?cHash=cce5d907b8367eb2a3f34284fb40a739", null, "https://pubmed.ncbi.nlm.nih.gov/34474414/", "https://pubmed.ncbi.nlm.nih.gov/35141465/", "https://pubmed.ncbi.nlm.nih.gov/35159045/", "https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20770", "https://www.sciencedirect.com/science/article/abs/pii/S1535610822001180?via%3Dihub", "https://pubmed.ncbi.nlm.nih.gov/35151693/", "https://pubmed.ncbi.nlm.nih.gov/34608631/", "https://onlinelibrary.wiley.com/doi/10.1111/cup.14178?af=R", "https://www.sciencegate.app/document/10.1016/j.canlet.2021.10.031", "https://www.researchgate.net/publication/357626201_Clinical_histopathological_and_prognostic_features_of_primary_cutaneous_acral_CD8_T-cell_lymphoma_and_other_dermal_CD8_cutaneous_lymphoproliferations_-_Results_of_an_EORTC_Cutaneous_Lymphoma_Group_Wor", "https://pubmed.ncbi.nlm.nih.gov/34870260/", "https://onlinelibrary.wiley.com/doi/10.1002/path.5872?af=R", "https://portal.research.lu.se/sv/publications/merkel-cell-polyomavirusnegative-merkel-cell-carcinoma-originatin", "https://onlinelibrary.wiley.com/doi/10.1111/exd.14447", "https://pubmed.ncbi.nlm.nih.gov/35212137/", "https://onlinelibrary.wiley.com/doi/10.1111/bjd.20869", "https://onlinelibrary.wiley.com/doi/full/10.1111/ced.15124", "https://pubmed.ncbi.nlm.nih.gov/34986285/", "https://link.springer.com/article/10.1007/s00105-021-04883-5", "https://www.sciencedirect.com/science/article/abs/pii/S0731708522000449", "https://link.springer.com/article/10.1684/ejd.2021.4028", "https://link.springer.com/article/10.1007/s00105-021-04827-z", "https://pubmed.ncbi.nlm.nih.gov/34431478/", "https://www.nature.com/articles/s41388-020-01576-6", "https://pubmed.ncbi.nlm.nih.gov/34281986/", "https://link.springer.com/article/10.1684/ejd.2021.4148", "https://onlinelibrary.wiley.com/doi/10.1111/cup.14066", "https://pubmed.ncbi.nlm.nih.gov/33496022/", "https://pubmed.ncbi.nlm.nih.gov/34347845/", "https://www.researchgate.net/publication/356840051_Differential_effects_of_PD-1_and_CTLA-4_blockade_on_the_melanoma-reactive_CD8_T_cell_response", "https://pubmed.ncbi.nlm.nih.gov/33533485/", "https://pubmed.ncbi.nlm.nih.gov/33439294/", "https://pubmed.ncbi.nlm.nih.gov/30333097/", "https://pubmed.ncbi.nlm.nih.gov/33332574/", "https://pubmed.ncbi.nlm.nih.gov/33861000/", "https://pubmed.ncbi.nlm.nih.gov/33768700/", "https://pubmed.ncbi.nlm.nih.gov/32574377/", "https://pubmed.ncbi.nlm.nih.gov/33786987/", "https://www.jmir.org/2021/7/e20708", "https://pubmed.ncbi.nlm.nih.gov/33838393/", "https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14447_g", "https://pubmed.ncbi.nlm.nih.gov/33960613/", "https://pubmed.ncbi.nlm.nih.gov/33491095/", "https://pubmed.ncbi.nlm.nih.gov/32707252/", "https://www.frontiersin.org/articles/10.3389/fonc.2021.672172/full", "https://pubmed.ncbi.nlm.nih.gov/32997839/", "https://pubmed.ncbi.nlm.nih.gov/34223939/", "https://pubmed.ncbi.nlm.nih.gov/33735811/", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833453/", "https://pubmed.ncbi.nlm.nih.gov/33706206/", "https://pubmed.ncbi.nlm.nih.gov/34166770/", "https://www.mdpi.com/2072-6694/13/10/2319", "https://pubmed.ncbi.nlm.nih.gov/33423009/", "https://pubmed.ncbi.nlm.nih.gov/34388516/", "https://pubmed.ncbi.nlm.nih.gov/33791209/", "https://link.springer.com/article/10.1684/ejd.2021.4030", "https://pubmed.ncbi.nlm.nih.gov/35107079/", "https://link.springer.com/article/10.1684/ejd.2021.4152", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696207/", "https://pubmed.ncbi.nlm.nih.gov/34299213/", "https://pubmed.ncbi.nlm.nih.gov/32479678/", "https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14619_g", "https://pubmed.ncbi.nlm.nih.gov/34661345/", "https://www.sciencedirect.com/science/article/abs/pii/S089684112100113X", "https://pubmed.ncbi.nlm.nih.gov/33394553/", "https://pubmed.ncbi.nlm.nih.gov/32506959/", "https://pubmed.ncbi.nlm.nih.gov/34591417/", "https://pubmed.ncbi.nlm.nih.gov/33792909/", "https://link.springer.com/content/pdf/10.1186/s13023-021-01863-9.pdf", "https://pubmed.ncbi.nlm.nih.gov/33219855/", "https://pubmed.ncbi.nlm.nih.gov/33870464/", "https://pubmed.ncbi.nlm.nih.gov/33605465/", "https://pubmed.ncbi.nlm.nih.gov/34249012/", "https://pubmed.ncbi.nlm.nih.gov/33170954/", "https://pubmed.ncbi.nlm.nih.gov/33878455/", "https://www.sciencedirect.com/science/article/abs/pii/S0959804921000952#:~:text=Patients%20with%20synchronous%20clinical%20stage%20III%20melanoma%20can,in%20patients%20with%20nodal%20macroscopic%20stage%20III%20melanoma.", "https://pubmed.ncbi.nlm.nih.gov/33655345/", "https://pubmed.ncbi.nlm.nih.gov/33521510/", "https://pubmed.ncbi.nlm.nih.gov/33480069/", "https://pubmed.ncbi.nlm.nih.gov/33279851/", "https://www.jidinnovations.org/article/S2667-0267(21)00034-5/fulltext", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582785/", "https://pubmed.ncbi.nlm.nih.gov/34102453/", "https://www.frontiersin.org/articles/10.3389/fonc.2021.765608/full", "/medien-kontakt/glossar/Tumors/?cHash=231a0cd23e385c9aa96a2e120c2fa07b", "/medien-kontakt/glossar/Multicenter/?cHash=c327ddb47a84bba25bc17a9ebe41ed45", "/medien-kontakt/glossar/Predictors/?cHash=4c4b240251db5939ebb2de5458c3e780", null, null, null, null, "javascript:linkTo_UnCryptMailto(%27iwehpk6ejbk9dwqpghejegWqgs%3Aza%27);", null, null, "/kliniken-zentren/", "/patienten-besucher/", "/zuweiser/", "/forschung/", "/karriere/", "/ueber-das-ukw/", "/frauenklinik/babygalerie/", "/medien-kontakt/presse/", "/medien-kontakt/presse/magazine/", "/medien-kontakt/presse/mediathek/", "/medien-kontakt/glossar/", "/medien-kontakt/spenden/", "/medien-kontakt/kontakt/", "/patienten-besucher/anreise/", "/recht/datenschutz/", "/recht/compliance/", "/recht/impressum/", "/recht/informationen-fuer-geschaeftspartner/", "/recht/vertraulichkeit/", null, "tel:+499312010", "/transfusionsmedizin/schwerpunkte/blutspende/blut-und-thrombozyten-spenden-am-uniklinikum-wie-geht-das/", null, "/startseite/datenschutzhinweis-facebook/", "/startseite/datenschutzhinweis-instagram/", "/startseite/datenschutzhinweis-twitter/", "/startseite/datenschutzhinweis-youtube/", "/startseite/datenschutzhinweis-linkedin/", "/startseite/datenschutzhinweis-xing/"]}